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CHAPTER 1; INTRODUCTION 
General introduction 
In 1980, researchers labeled living cells with [^H] palmitate and discovered for the first 
time that a variety of lysate proteins incorporate the 16 carbon fatty acid (1). This 
modification was termed "palmitoylation" and preceded the discoveries of other covalent 
lipid modifications, including myristoylation and isoprenylation. In the last 18 years, many 
papers have been written identifying specific palmitoylated proteins observed in that first 
lysate. The membrane-binding proteins range fi-om the transferrin receptor, an iron-binding 
trans-membrane protein, to the cytoskeletal microtubule protein, tubulin (2,3). 
The palmitate addition to proteins has been implied to be required for the function of 
several proteins. In non-palmitoylated mutants of endothelial nitric oxide synthase, the 
protein is unable to bind to caveloae sub-domains of the membrane where it functions (4). 
The alpha subunits of the heterotrimeric Gs and Gq proteins require palmitoylation for 
membrane binding and interactions with other subunits, beta and gamma (5-7). In 
unpalmitoylated mutant G protein coupled receptor kinases, activation of effectors is 
inhibited rather than activated (8,9). The neuronal protein, SNAP-25, thought to be involved 
in vesicular trafficking, cannot bind membranes where it is normally localized(lO). So, the 
palmitoylation modifications seem to be required in some cases for the normal function of 
proteins. 
An interesting point about the palmitoylation of proteins, which will be fiarther 
discussed below, is that it is a reversible reaction. Palmitate is cycling on and off proteins at 
a rate that is usually much faster than the life of the protein. If this labile reaction is regulated 
in some way, then it has been suggested that the activity of the modified protein is likewise 
regulated. Several examples of this regulation have been described and will be discussed. The 
search for methods of palmitoylation regulation has been underway since the discovery of its 
reversibility. 
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In this investigation, I have used the membrane-associated protein, H-Ras, as a model to 
study the regulation of palmitoylation. H-Ras is a small, monomeric GTPase that is dually 
palmitoylated. The palmitate modification of H-Ras has been shown to be reversible. 
However, no evidence has been provided to indicate that the palmitoylation of H-Ras is 
regulated. In the following dissertation, I will provide evidence to show that the reaction is 
indeed regulatable. In addition, I will furnish at least two possible situations where palmitate 
turnover rate on H-Ras is modified: treatment with S-nitrosocysteine and the GTP-binding 
state of the protein. 
Dissertation Organization 
This dissertation comprises a general introduction to lipid modifications, two 
manuscripts, and a summary. The literature review following immediately includes 
descriptions of the lipid modifications of H-Ras and possible regulatory mechanisms for this 
modification. Chapters 2 and 3 are manuscripts in preparation for submission to the Journal 
of Biological Chemistry. The first paper, "S-nitrosocysteine increases palmitate turnover on 
H-Ras while decreasing activity and signaling in NIH 3T3 cells," describes the first 
observation of H-Ras palmitoylation regulation by a nitrosothiol and suggests a possible 
mechanism for this activity. The second manuscript, "Palmitate turnover at the C-terminus 
depends on activation state of H-Ras," presents the results of a study measuring the 
depalmitoylation rates of activated H-Ras mutants and comparing them to those of wild type 
H-Ras. A conclusion chapter follows that includes a summary of the results observed in this 
research, future directions of study, and overall implications of the work on the lipid 
modification field. 
Literature Review 
Ras signaling 
Many pathways have been found that regulate functions important to necessary life 
processes. One of the first signal transduction pathways discovered and subsequently 
studied was the Ras-Raf pathway. Only four years ago, this pathway included many 
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unknown proteins, many of which have since been identified and ordered. Even now, many 
questions remain about the specific interactions in the pathv/ay. It is evident, however, that 
the pathway is not linear but has many cross-linkages that paint an even more complex 
picture. Because the messages transmitted along this pathway affect gene expression, 
studying the interactions between these proteins will yield insight into cell differentiation and 
growth. 
The Ras-Raf pathway is involved in cell differentiation in several cell types of different 
species. When the pathway is activated in pheochromocytoma PC-12 cells, differentiation 
occurs, leading to a neuron-like cell type (11). Drosophila require proper Ras-Raf signaling 
during eye differentiation (12). In the nematode C. elegans, disruption of the pathway leads 
to loss of vulva differentiation and death (13). 
In addition to cell differentiation, cell growth is regulated by the Ras-Raf pathway. 
Many of the proteins in this pathway, from cell surface receptors to transcription factors, are 
encoded by proto-oncogenes. When mutationally activated, they produce unregulated growth 
that can lead to cancer. For instance, when v-Ras is expressed in NIH 3T3 fibroblast cells, 
cells are transformed and the pathway is constantly active (14). Understanding the 
regulation of the Ras-Raf pathway will lead to further insights into the mechanisms of cancer. 
Ras proteins are small, monomeric GTPases. They share a close homology with the 
alpha subunits of the larger heterotrimeric G proteins. Four types of mammalian Ras proteins 
have been characterized: H-Ras, N-Ras, and K4A- and K4B-Ras, which are two differently 
spliced RNA products. The sequences of these subtypes are almost 90% identical, differing 
only in the C terminal region of the proteins(15). These proteins are able to bind and 
hydrolyze GTP(16). In the GTP-bound state, Ras is active. It is the change in conformation 
upon GTP-binding that allows Ras to interact with effector molecules, including Raf kinase 
and GTPase activating protein (GAP). Upon binding GAP, the Ras intrinsic GTPase 
activity is increased and GTP is hydrolyzed to GDP. The resulting change in conformation 
collapses the effector binding domain, inactivating Ras. Upon stimulation with growth factor 
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ligands, another protein, Son of Sevenless (SOS), assists Ras in releasing the GDP, which 
allows GTP to enter the nucleotide binding pocket(17). This starts the cycle of activation 
again. 
When Ras is "active," it can bind to effectors. One function that has been attributed to 
Ras is that when binding the effector, Raf, it targets and tethers the kinase to the plasma 
membrane (18,19). When Raf reaches the plasma membrane, it is activated and 
phosphorylated by as yet unidentified proteins. Upon its activation, Raf phosphorylates 
another protein in a kinase cascade that eventually leads to the cell nucleus. There, the last 
kinase in the cascade, mitogen-activated protein kinase (MAPK), phosphorylates DNA 
binding proteins and regulates the transcription of early response genes (20). So, Ras is one 
of many proteins in this pathway. However, its action and regulation are essential. When the 
intrinsic GTPase is inactivated by a mutation in that region, Ras is bound to GTP and 
constitutively active (21). The constant signal sent through Raf to proteins inducing DNA 
synthesis leads to unregulated growth and cancer. In fact, mutations in Ras genes are 
identified in almost 50% of human tumors (22). In contrast, if Ras is unable to bind GTP and 
is inactive, Raf is not localized to the plasma membrane and the circuit is broken. This 
eventually results in cell death (23). The regulation of Ras is directly related to the regulation 
of the pathway, so study is vigorous in this area. 
Lipid modifications of H-Ras 
Ras activity has been found to be dependent on its ability to associate with plasma 
membranes. This mostly hydrophilic protein is able to localize to membranes through 
hydrophobic lipid modifications occurring post-translationally. When proteins are separated 
by SDS-PAGE, pulse-chase experiments show Ras is synthesized first as a cytosolic protein 
with a molecular weight of approximately 22 KDa. The protein matures and moves rapidly 
into the membrane as a 21 KDa protein. The ability of Ras to move into the hydrophobic 
cell fraction results from the isoprenylation of the protein. Additional palmitate lipid 
modifications increase the hydrophobicity of several of the Ras proteins. Without these lipid 
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additions, Ras is unable to associate with the plasma membrane and cannot function, causing 
the cessation of cell response to certain stimuli. By studying Ras lipid modifications and 
their regulation, it may be possible to find ways to either synthetically control Ras signaling 
or complement the endogenous mechanisms involved in regulating Ras activity. 
The isoprenylation of Ras is directly related to its fimction. Ras can target and tether 
Raf proteins at the membrane easily because Ras is bound at the cell membrane almost 
immediately after synthesis by ionic and hydrophobic interactions. All four types of p21Ras 
are modified post-translationally by addition of an isoprenoid at a C terminal cysteine. A 
famesyltransferase has been discovered that attaches a famesyl, which is made as an 
intermediate during cholesterol synthesis, to newly synthesized Ras. The addition of this 
isoprenoid is accomplished by creating a thioether bond at a CAAX motif, where "C" is the 
cysteine that is modified, the "A's" are aliphatic residues, and the "X" is either a methionine 
or a serine. After this addition, the -AAX residues are cleaved and the C terminus 
methylated, resulting in the change in molecular weight observed in chase experiments (24-
26). It has been demonstrated that without this modification Ras is not targeted to the 
membrane but remains in the cytosol. Also, cytosolic Ras has been found to be inactive, i.e., 
unable to tether Raf to the cell membrane (27). In fibroblasts, active but unfamesylated Ras 
mutants can no longer cause cell transformation, or unregulated cell growth. The addition of 
another lipid, myristate, returns the transformation ability to unfamesylated Ras mutants 
(28). From these experiments, the function of the isoprenoid on Ras has been suggested to be 
required for membrane targeting and tethering. Because Ras ftxnctions with effectors only at 
the membrane, isoprenylation is crucial for the activity of Ras. 
Palmitoylation is another modification affecting Ras function that occurs in several of the 
Ras proteins. All four p21Ras types have additional modifications that are believed to assist 
in membrane binding. H-, K4A- and N-Ras are modified by the thioester linkage of one or 
more palmitates at cysteines near the isoprenylation site (24-26,29). Several theories about 
exactly how this modification assists in membrane binding exist, but it is evident that the 
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increased hydrophobicity of the protein could increase hydrophobic attraction, whether the 
fatty acids intercalate into the membrane lipids or lay along the inner leaf of the bilayer. 
The exact function of the palmitoyiation modification is as yet undefined. Increasing 
hydrophobicity of Ras would likely allow it to more easily associate with membranes. H-
Ras with site-specific mutations at the 181 and 184 cysteines is found in the cytosol rather 
than at the plasma membrane and is less transforming than wild-type palmitoylated H-Ras 
(28). This result indicates that the palmitate modifications on Ras are required for membrane 
binding and is involved in the activity of the protein. Additionally, H-Ras mutants with only 
one of the palmitate target cysteines modified are not targeted to appropriate membranes. 
The 181S H-Ras mutant when expressed in NIH 3T3 fibroblasts is associated with Golgi 
membranes, rather than the plasma membrane (28). This suggests that the palmitoyiation of 
H-Ras is also required for proper targeting of the protein. Palmitoyiation, in addition to 
isoprenylation, allows H-Ras to target and bind appropriate membranes. Therefore, the 
palmitate addition to H-Ras may be a likely target for regulating the protein. 
Mechanism of palmitoyiation 
Palmitoyiation is a requirement for H-Ras function. Because of its importance, it is likely 
that this modification is under some type of cellular regulation. Increasing the likelihood of a 
regulation mechanism, Ras palmitoyiation is a transient modification with a half-life of about 
90 minutes in normal circumstances (30). It may be possible that by changing the rates of 
palmitate cycling that Ras function could also be affected. The purpose of study in our 
laboratory and others has been to identify cellular devices that actively regulate 
palmitoyiation of proteins and thereby regulate protein function. 
Enzymes versus autoacylation 
The method of fatty acid attachment is still not fully understood. Debate continues on 
whether or not palmitoyltransferases exist that attach palmitates to proteins. So far, several 
proteins have been identified that have been named palmitoyltransferases. However, the 
proteins have defied purification. In 1991, it was reported that a cell-free lysate was able to 
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palmitoylate H-Ras (31). This result indicated that a cellular enzyme might be responsible 
for palmitate transfer from palmitoylCoA to a protein. Liu et al. were able to purify a 
protein that actually seemed to transfer a palmitate to H-Ras from palmitoylCoA (32). It 
was the first published report of an enzyme that could acylate a protein. However, these 
researchers later discovered that their result was an artifact. The protein they had identified 
was a new thiolase that could palmitoylate proteins, but only as a side reaction (Gelb, 1997, 
personal communication). Two additional palmitoyltransferase enzymes have been identified 
and partially purified from other laboratories (33,34). Both are membrane-bound and show 
some protein specificity. Their activities are affected by heat, denaturation, and changes in 
pH. Unfortunately, these enzymes defy total purification and their activities are very labile. 
The purified enzyme could be used to further study the palmitoylation regulation of many 
signaling proteins. 
Early studies were conducted attempting to identify a common palmitoyltransferase 
target domain in Ras proteins. During investigations in our laboratory, Buss discovered that a 
signaling motif like that of the isoprenylation signal CAAX is not evident for the attachment 
of palmitates (24,28). After modifying many of the residues around target cyteines 181 and 
184 in v-H-Ras, no change in palmitoylation occurred, indicating that a signaling motif in this 
area does not exist. In addition, many proteins are palmitoylated, yet the amino acid 
sequences around the target cysteines seem to have no pattern. Recently, Lu and Hofmann 
suggested that no signaling motif for lipid attachment is required, but physical access of the 
protein to a palmitoyl deacylase regulates the removal of the fatty acid (35). 
It has been suggested that there is no need for a palmitoyltransferase enzyme. One 
argument for this is the finding that many proteins can be autoacylated in vitro. Duncan et. al. 
reported that purified G protein sub-units can become rapidly palmitoylated in the presence 
of palmitoylCoA alone (36). The rate of palmitoylation was approximate to that measured in 
vivo. Further, this study indicated that this reaction is heat- and pH-sensitive. Additionally, 
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the reaction did not occur under denaturing conditions. Likewise, other proteins, such as H-
Ras, can be autoacylated in vitro (37,38). 
The existence of a palmitoyltransferase has also been studied with kinetic and 
thermodynamic methods. Quesnel et. al. observed the autoacylation of several proteins and 
peptides, all in vitro (39). Recently, a group of newly identified proteins, the acyl-CoA 
binding proteins have also been characterized (40). These proteins, in a test tube, inhibit 
spontaneous acylation of lipopeptides that are normally palmitoylated rapidly. The 
relationship between these binding proteins and long chain fatty acid-CoAs has been 
quantitatively characterized. Using cellular concentrations of acyl-CoA binding proteins and 
normally lipidated proteins, results indicated that the palmitate half-life on proteins will be 
approximately ten hours, much longer than observed in vivo which is in the range of minutes. 
These studies suggest that autoacylation may occur in cells; however, the reaction is limited 
by the existence of acyl-CoA binding proteins. This would indicate that palmitoylation of 
proteins is occurring through another mechanism, most likely by an enzyme. 
Studies continue to determine whether palmitoylation is enzyme catalyzed or not. The 
discovery and purification of a palmitoyltransferase would benefit researchers in the field. 
We could more easily leam about possible regulation mechanisms used by the cell. However, 
autoacylation is a possible reaction in vivo. If an enzyme is responsible for transfer of 
palmitate to proteins, the mechanism responsible for preventing autoacylation must be 
discovered. The means of inhibition may be the acyl-CoA binding proteins, but more work 
must be done in vivo before the hypothesis is accepted. Until definite results are made, the 
mechanisms responsible for palmitoylation of proteins, specifically H-Ras, are unknown. 
Because of this, we cannot determine how the reaction is regulated by looking at the reaction 
mechanism itself. Instead, we have studied the palmitoylated proteins themselves. By 
affecting the palmitate target cysteines and protein conformation, we can change rates of 
palmitoylation and thus regulate the reaction. 
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Regulation of dynamic palmitoylation 
If the cycle of palmitoylation and depalmitoylation was better understood, specific 
models of regulation for several transforming proteins, including Ras, could be designed. 
Several laboratories are studying this regulation, including our own. However, only a few 
agents have been found that affect palmitoylation. 
Recently, a paper by Hess et al. indicated one possible regulatory mechanism of the 
palmitoylation cycle. By treating neuronal PC-12 cells with nitric oxide (NO)-producing 
agents, a decrease in the incorporation of [^H] palmitate was observed in a variety of 
proteins. Specific proteins that were affected included GAP-43 and SNAP-25. The authors 
hypothesized that NO was directly binding the sulfur of the cysteine(s) that would normally 
be palmitoylated, producing a nitrosothiol bond (41). This would block attachment of the 
palmitate, explaining the decrease of [^H] palmitate incorporation into these proteins in the 
PC-12 cells. 
It has long been observed that NO binds thiols transiently in oxidizing conditions, like 
those used commonly for cell culture (42). However, NO and related nitroso compounds can 
attack hemes as well as react with superoxides to produce peroxjoiitrite, a cytotoxic agent 
(43,44). The physiological effects of these NO reactions are varied. In neurons, NO acts as 
a signaling messenger released from a post-synaptic neuron in response to glutamate binding 
at a NMDA receptor. NO has two mechanisms by which it causes effects in this system. 
First, after stimulation and glutamate binding, NO is released from the post-synaptic cell and 
diffuses to the pre-synaptic neuron or neighboring astrocytes. The free radical binds the iron 
in the heme of soluble guanylate cyclase and stimulates the enzyme to produce increased 
intracellular cGMP levels, and in doing so decreases neurotransmitter release. The second 
example of the diversity of NO acting in the neiu-on, NO binds neighboring cysteines in the 
NMDA receptor-channel complex regulatory site and creates a disulfide which blocks the 
channel (45). This latter reaction occurs independently of cGMP. Besides neuronal 
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signaling, NO is also involved in cardiac contraction, smooth muscle relaxation, and 
macrophage cytotoxicity, as well as a myriad of other physiological functions (46,47). 
Effects of nitric oxide seem almost ubiquitous: no protein appears to be safe from it. It 
has been hypothesized that the diversity of nitric oxide metabolites allows it to affect various 
proteins. So, it is not the nitric oxide radical that is responsible for all of these effects, but the 
metabolites such as nitrosothiols and peroxynitrite. Any study that finds an effect by NO 
treatment must more accurately define the actual causal agent. This can be done using 
pharmaceutical products that synthesize only one metabolite. Over time, however, even 
these metabolites will react with cellular proteins or oxygen and cycle between ntirosothiols 
and peroxjmitrites (43,44,48). When these oxidants cause an effect, it is difficult to design a 
model because of the seeming promiscuity of the NO products. In the present study, we 
have tested the effects of cell treatment with a variety of products to best delineate the agent 
that is responsible for changes in palmitoylation of proteins, including H-Ras. 
Another model of regulation of palmitate cycling of proteins was described by 
Wedegaertner and Bourne, 1994. They have discovered that isoproterenol, a (3-adrenoreceptor 
agonist, can increase turnover rates of palmitate binding on Gas, with a change in the 
protein's localization from membrane to cytosol (5). Gas is a sub-unit of a heterotrimeric 
GTPase, and is closely related to the Ras GTPase. More recent data from their laboratory 
has allowed them to build a complex model of the relationship between activation and 
palmitate turnover. When GTP binds the Ga, two other subunits, p and y, are released. This 
allows a constitutively active palmitoyl-deacylase opportunity to cleave the palmitate 
thioester bond at the Ga amino terminus. The subunit is released into the cytosol and re-
palmitoylated. Upon palmitoylation. Gas is again able to return to the membrane and be 
activated. The Py subunits are hj^othesized to protect the palmitoylated cysteine from the 
thioesterase (6). This model indicates a dependent relationship between palmitoylation and 
activation of the GTPase. 
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Isoproterenol can also increase the palmitate turnover of the palmitoylated trans­
membrane protein, P adrenergic receptor protein. This protein is directly upstream of Gas in 
another signaling pathway. During prolonged exposure to isoproterenol, the protein becomes 
less palmitoylated, as the depalmitoylation rate is so rapid. Here, the palmitate turnover is 
not immediately associated with translocalization into the cytosol. However, by continued 
isoproterenol treatment, the receptor is increasingly internalized (49). This may indicate that 
a relationship exists between the regulation of palmitoylation and desensitization. 
Obviously, the cycle of palmitoylation/depalmitoylation of some proteins can be regulated in 
vivo. Discovery of potential regulation mechanisms is important to understanding regulation 
of the Ras-Raf signaling pathway. 
Summary of Current Research 
Slowly, the regulatory models of palmitoylation are being identified for some proteins. 
It seems that the reversible palmitate addition to proteins is a possible mechanism for protein 
function control. However, no one has yet found a regulatory mechanism for the 
palmitoylation of H-Ras. Because activated H-Ras is found in tumors and associated with 
unregulated cell growth, alternative methods of protein regulation would be a significant 
discovery. 
We have identified and characterized two methods by which the palmitoylation of H-Ras 
can be effected. While Hess et al. (1993) showed that the palmitate addition of lysate 
proteins in neuronal PC-12 cells was decreased upon nitric oxide treatment, we have shown 
that H-Ras actually increases [^H] palmitate incorporation when cells are treated with the 
oxidant, S-nitrosocysteine. Our results indicate that S-nitrosocysteine is simultaneously 
decreasing H-Ras activity and signaling. We cannot conclusively say that increased H-Ras 
palmitate tumover is interdependent on activity in this paper. However, we have 
characterized the effects of S-nitrosocysteine on the model system. In future experiments S-
nitrosocysteine may be used as a tool to more fiilly explore the possibility that increased 
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palmitate turnover indicates decreased H-Ras activity. This is the first example of palmitate 
rate modification on H-Ras to be identified. 
The second regulatory mechanism we propose is that the activation state of H-Ras is 
related to rates of palmitate turnover. Using activated and dominant-negative mutants of H-
Ras, we show that palmitate turnover of primarily GTP-bound Ras is faster than that of 
primarily GDP-bound H-Ras. This work is in agreement with the Wedegaertner and Bourne 
data with the isoprotemenol activation of Gas and its increased palmitate turnover (5). We 
that the change in conformation of H-Ras upon GTP binding somehow reveals the palmitate 
at the C terminus to deacylases. 
These results indicate that H-Ras palmitoylation is regulated. Some evidence can be used 
to suggest that changes in palmitate turnover rates are related to the activity and signaling of 
the protein. This is another example of the importance in understanding the cellular 
mechanisms of regulating protein function through this lipid modification. 
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CHAPTER 2; S-NTTROSOCYSTEINE INCREASES PALMITATE 
TURNOVER ON H-RAS WHILE DECREASING ACTIVITY AND 
SIGNALING IN NIH 3T3 CELLS 
A paper prepared for submission to Journal of Biological Chemistry 
Tara L. Baker and Janice E. Buss 
ABSTRACT 
H-Ras is a small GTPase, related to the alpha sub-unit of the heterotrimeric G proteins. 
It is involved in signaling pathways through the Raf kinase, leading to cell proliferation and 
differentiation. H-Ras is lipid modified at its C terminus. A stable addition of an isoprenoid 
is located at its terminal 186 cysteine (1). Two cysteines at positions 181 and 184 are 
reversibly palmitoylated (2). The palmitoylation of H-Ras has been hypothesized to be 
required for targeting of H-Ras to the plasma membrane and interactions with effector 
proteins (3-8). This study showed that treatment of H-Ras transfected NIH 3T3 cells with S-
nitrosocysteine (SNC), a nitrosothiol, doubles the rate of [^H] palmitate incorporation on H-
Ras. This increase in palmitate replacement with 4 mM SNC is dose and time dependent. 
The palmitate turnover rate, measured with [^H] palmitate pulse-chase experiments, is also 
increased in response to exogenous treatment with SNC. The increased rate of palmitate 
turnover on H-Ras coincides with a decrease in OTP-binding. SNC treatment also inhibits 
normal Erk phosphorylation during serum stimulation. This result concurs with the 
suggestion that SNC decreases the activity of H-Ras and inhibits signaling through a Ras-
dependent pathway. The ability of other oxidants, including larger nitrosothiols (SNAP and 
S-nitrosoglutathione), peroxynitrite, and hydrogen peroxide to increase palmitate replacement 
was tested. SNC causes the greatest increase in palmitate replacement, but other oxidants 
were able to cause an increase also. These results suggest that SNC, and possibly these other 
oxidants, can be used as a tool to increase palmitate turnover on H-Ras. 
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INTRODUCTION 
The Ras-Raf kinase cascade is important for regulating cell growth and differentiation. A 
growth factor ligand binds its receptor tyrosine kinase on the outside of the cell membrane. 
The message is then transmitted through several cytosolic protein kinases before ending in the 
nucleus. Successful signaling leads to cell differentiation or growth. One protein that is 
required for proper transmittal from the plasma membrane to these cytosolic kinases is the 
small, membrane-bound G protein, Ras. Its purpose has not been fully revealed, but it has 
been shown that another protein in the signaling pathway, Raf, requires localization to the 
membrane for its proper signaling. One of the hypothesized roles of Ras is to transfer the 
Raf protein from the cytosol to the plasma membrane (9-11). 
Ras is a monomeric GTPase, much like the alpha sub-unit of the larger trimeric G 
proteins. In its GTP-bound conformation, Ras is active and may bind effectors, such as Raf. 
Its intrinsic GTPase activity is enhanced when bound to GTPase activating protein 
(RasGAP), and the GTP is hydrolyzed to GDP (6,12). The resulting change in 
conformation leads to the release of bound effectors and cessation of signaling, and therefore 
stops signaled cell growth. Oncogenic Ras has a disabled GTPase, so it is unable to hydrolyze 
its bound GTP and leaves the protein in an active conformation. The resulting effect in NIH 
3T3 cells is a transformed phenotype (13). In approximately 50% of himian tumors, a 
mutated Ras has been found (14). 
A requirement for Ras activity is proper localization to the cell plasma membrane(6-
8,15,16). If the role of Ras is to transfer the Raf protein from the cytosol to the plasma 
membrane, it can be concluded that Ras must be at the membrane to fulfill its function. Ras 
has lipid modifications that allow it to efficiently bind the hydrophobic plasma membrane. 
Four mammalian Ras proteins, H-Ras, N-Ras, K4A and K4B-Ras, have been discovered, and 
each has an isoprenoid attached at a CAAX (where "C" is cysteine, "A" is a aliphatic residue 
and the "X" any amino acid) sequence at the C terminus (1,17). An isoprenoid, usually 
famesyl, is bound by a stable thioether linkage to cysteine. The last three amino acids are 
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cleaved and the carboxy terminus methylated. The isoprenoid has been shown to be required 
but not sufficient for membrane binding (8). 
H-Ras, N-Ras, and K4A-Ras have an additional lipid modification at the C terminus. At 
either one cysteine, as in the case of N-Ras and K4A-Ras, or two cysteine residues, as in the 
case of H-Ras, palmitate is bound by a labile thioester bond (17). In H-Ras mutants that 
have the normal palmitoylated cysteines at sites 181 and 184 changed to serines, the protein 
cannot bind the membrane efficiently and is no longer transforming in NIH 3T3 cells (8). It 
has also been shown that H-Ras requires both palmitates for proper locaHzation to the 
plasma membrane. A 181S mutant still palmitoylated at the 184C site is mislocalized to the 
Golgi membrane (28). Previous work has shown that Ras palmitoylation is required for 
efficient membrane localization and binding. 
Recent experiments have indicated that the palmitoylation of other proteins may also be 
involved in their activity. Because of the modification's lability, the tumover rate of 
palmitoylation is faster than that of the protein itself. In addition to proper membrane 
localization, it has been hypothesized that palmitoylation may be regulated and important to 
the activities of certain proteins. The activation of the P adrenergic receptor and Gas by the 
agonist isoprotemol increases the palmitate tumover rate of these two proteins (18-20). In 
addition, treatment of endothelial cells with bradykinin has been reported to increase 
depalmitoylation of endothelial nitric oxide synthase (eNOS) while activating the protein 
(21). Current models suggest that the palmitate tumover of some proteins, including the 
Gas, p adrenergic receptor and eNOS, is somehow related to the activation of the proteins. 
The exact nature of this relationship is so far unknown. 
One other agent that has been suggested to affect the palmitoylation of various proteins 
is nitric oxide. Nitric oxide is a naturally synthesized radical that affects platelet aggregation, 
macrophage killing, capillary relaxation, penile erection, uterine contraction, as well as many 
other physiological fiinctions (22-26). The radical is metabolized in seconds, though results 
often last much longer. It has been suggested that more stable metabolites of nitric oxide, or 
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NOx, may be the causative agents in regulating the mentioned functions (27-29). Some of 
these metabolites include nitroso-thiols and peroxynitrites. Various synthetic NOx 
compounds are commercially available. Hess et al. (30) showed that two NOx producers, 
SIN-1, a compound that produces peroxynitrite (ONOO-), and S-nitrosocysteine (SNC), a 
cysteinyl nitroso-thiol, caused an over-all decrease in palmitate incorporation in neuronal cell 
lysate proteins. 
In addition, nitric oxide and its metabolites have been shown to affect Ras GTP-binding 
and signaling. Lander et al. reports that the population of endogenous Ras in Jurkat cells 
becomes increasingly more GTP-bound and activated during nitric oxide treatment. It has 
also been reported that the nitric oxide target of this effect is a nitrosylatable cysteine at 
position 118, in the GTP-binding pocket of Ras (31-33). These results indicate that Ras is 
available to exogenously applied nitric oxide metabolites and may be one of the target 
proteins for these compounds. 
In NIH 3T3 cells simultaneously treated with SNC during [^H] palmitate labeling, we 
saw a similar decrease in palmitate incorporation. However, when looking specifically at 
stably transfected H-Ras in these cells, an increase in palmitoylation of the protein during 
treatment with SNC was observed. Additionally, depalmitoylation rates of H-Ras were 
increased during treatment. This is the first example of deliberate manipulation of 
palmitoylation of H-Ras. Using SNC as a tool to synthetically increase palmitate tumover, 
the effects on the activity of H-Ras by looking at effector binding and over-all pathway 
signaling were examined. Signaling and palmitoylation of H-Ras are affected by exogenous 
treatment of cells with SNC. 
METHODS 
Cell culture 
NIH3T3 cells stably transfected with v-H-Ras (gift of B. Willumsen, University of 
Copenhagen), c-H-Ras, and 118S c-H-Ras ( both gifts of L. Quilliam, Indiana State 
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University) were grown at 10% CO2 in Dulbecco's Modified Eagle's Medium supplemented 
with 10% calf serum (Hyclone). 
Oxidants 
A 100 mM S-nitrosocysteine solution was prepared by solubilizing equimolar amounts 
of sodium nitrate (Fisher) and L-cysteine (Sigma) in water. Concentrated hydrochloric acid 
was added to 0.5 M. Control nitric oxide-depleted SNC was made at least one week prior to 
experiment. Before addition to cell media, acidic SNC was mixed with IM NaOH to make 
200 mM NaOH. Because the nitric oxide gas emitted is lost over time, additional 4 mM SNC 
was added every 30 minutes. A 100 mM S-nitrosoglutathione solution was made and used 
similarly, substituting reduced glutathione (Sigma) for L-cysteine. SIN-1 (Alexis), SNAP 
(Alexis), NOC-18 (Alexis), NOC-15 (Alexis) and hydrogen peroxide (Fisher) were diluted in 
water and added directly to media. 
Radiolabeling and Immunoprecipitation 
Palmitate incorporation was measured by labeling confluent cells with 0.5-1 mCi 
[^H]palmitate (Dupont/NEN) in media containing non-essential amino acids , 20 mM Hepes, 
pH 7.2, 25 mg/mL cycloheximide, and 10% calf serum(34). Labeling was stopped at times 
described by rinsing cells twice with Tris-buffered saline and lysing cells in a HI-SDS RIP A 
buffer (0.15M NaCl, 50 mM Tris (pH 7.0), 1% Aprotinin (Calbiochem), 1% Na-
deoxycholate, 1% Nonidet P-40 (Unites States Biochemical), 0.5% SDS). Depalmitoylation 
was measured by labeling cells for 3 hours, then incubating for varying time periods in similar 
but non-radioactive media containing 200 |iM palmitic acid (Sigma). After radiolabeling, 
samples were rinsed and lysed directly in high SDS-RIPA buffer for immunoprecipitation. 
Extracts of whole cell fractions were incubated on ice for 1 hour with a mouse 
monoclonal antibody specific for H-Ras (146-3E4, Quality Biotech), a mouse anti-transferrin 
receptor antibody (Zymed), or a rabbit anti-caveolin-1 antibody (Transduction Labs), coated 
on fixed Staphylococcus aureus cells (Pansorbin; Calbiochem) conjugated to goat anti-mouse 
heavy and light chain IgG. The immunoprecipitates were washed, resuspended in special 
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sample buffer without P-mercaptoethanol (2% SDS, lOmM Na2P04, pH 7.0, 10% glycerol, 
0.05% DTT, and 0.02% bromophenol blue), resolved by SDS-PAGE, transferred to PVDF 
membrane and, as needed, sprayed with En^Hance (DuPont/NEN) for fluorography or 
developed with antibody for immunoblot analysis. 
GTP/GDP Determination 
Confluent cultures of NIH 3T3 cells were grown over-night in 1% calf serum. Cells were 
then radiolabeled with 0.5-1 mCi [^^P] inorganic phosphate (Dupont/NEN) for 4 h in 
phosphate-free media containing 1% calf serum. Cells were rinsed with PBS suspended in 
GTP Lysis Buffer containing 50 mM Tris-HCl (pH 7.4), 20 mM MgCl2, 150 mM NaCl, 
0.5% (v/v) Nonidet P-40, Aprotinin (20 mg/mL), 1 mM EGTA, and 1 mM Na3V04. 
Insoluble material was removed by centrifugation at 750 g for 3 minutes. Supematants were 
cleared with 50% (v/v) BSA-coated charcoal in lysis buffer then H-Ras proteins captured by 
immunoprecipitation using the GTP Lysis Buffer above. H-Ras and its bound nucleotides 
were eluted by heating to 60 C for 5 minutes in a minimal volume of buffer containing 20 mM 
Tris-HCl (pH 7.4), 2 mM EDTA, 2% (w/v) SDS, 2 mM GDP, and 2 mM GTP. The eluants 
were cleared by centrifiigation at 10,000 g for 5 minutes. Then samples were spotted on 
polyethyleneimine cellulose plates (J.T. Baker) and separated with 0.75 M KH2PO4 (pH 
3.4). Plates were dried and exposed to pre-flashed film using screen enhancers. 
Erk activation experiments 
Transfected NIH 3T3 cells were serum-starved for 2-4 hr. Fresh or nitric oxide-depleted 
(2-7 days old) SNC was diluted to 4 mM in media containing 10% BCS. Serum-free media 
was replaced with either control or fresh SNC in 10% semm containing media for specified 
times. Cells were rinsed with TBS and lysed in IX sample buffer. Proteins were separated 
by SDS-PAGE and transferred to PVDF membranes. Erk was detected by immunoblotting 
with a Rabbit monoclonal antibody (Santa Cruz). Bands at 42 and 44 KDa were considered 
unphosphorylated and those at approximately 43 and 45 KDa were considered the activated, 
phosphorylated Erk proteins. 
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Immunoblotting 
Proteins collected by acetone precipitation or immunoprecipitation were resuspended in 
electrophoresis sample buffer. After separation by SDS-PAGE, proteins were transferred 
electrophoretically to PVDF membranes and non-specific protein binding was blocked by 
incubating the membrane in 1.25% non-fat dry milk in Tris-buffered saline overnight. 
Membranes were probed with the H-Ras-specific mouse monoclonal antibody, 146-3E4 
(Quality Biotech), rabbit Erk-1 antibody (Santa Cruz), or rabbit polyclonal Caveolin-1 
antibody (Transduction Labs). Biotinylated secondary antibodies (anti-mouse or anti-rabbit. 
Vector) were used with development by alkaline phosphatase (Vector) using the 
manufacturer's protocol. 
RESULTS 
S-nitrosocysteine affects palmitate incorporation of proteins 
Hess et al. (30) showed that when the neuronal-like cell types, PC-12 and dorsal root 
ganglion (DRG) cells, were labeled with [^H] palmitate in the presence of S-nitrosocysteine 
(SNC) and SIN-1, a producer of peroxynitrite (ONOO-), palmitate incorporation was 
decreased overall. Two proteins specifically from the lysates were identified, SNAP-25 and 
GAP-43, and their palmitoylation was obviously decreased (30). Because these experiments 
were performed in neuronal cell Unes, it was unknown whether SNC could cause a similar 
decrease in palmitate replacement in other cell types. 
To determine if general protein palmitoylation is affected by SNC in NIH 3T3 
fibroblasts, three proteins were immunoprecipitated after simultaneous [^H] palmitate 
labeling and SNC treatment. The proteins differ in their membrane localizations and 
functions. The first protein, transferrin receptor, is a trans-membrane protein involved in iron 
endocytosis, and localized on clathrin-coated pits (35). Caveolin, a second palmitoylated 
trans-membrane protein, is localized in caveolae and hypothesized to be involved in 
pinocytosis and organization of cell signaling molecules (36-38). The normal wild-type H-
Ras protein (WT) is membrane-associated through hydrophobic lipid modifications and has 
23 
been identified in membrane sub-domains that are termed "caveolae", but are also found 
outside of the caveolae microdomains (39). Palmitoylation of these proteins might play 
different roles in membrane binding, targeting, or protein interactions, though the functions of 
the palmitate modifications have not yet been defined. 
It is important to note that the current model of palmitoylation includes palmitate 
addition shortly after protein synthesis. The palmitates then cycle on and off the protein. In 
these experiments, cells were labeled with [^H] palmitate in the presence of cycloheximide to 
inhibit protein synthesis, so palmitate replacement on pre-existing proteins rather than the 
lipid modification of newly synthesized proteins was observed. 
Simultaneous [^H] palmitate radiolabeling and 4 mM SNC treatment of wild-type H-Ras 
(WT) stably transfected NIH 3T3 cells were done for 1 hr. SNC spontaneously breaks down 
into nitric oxide and cystine, a natural by-product. Control samples were labeled with [^H] 
palmitate in the presence of "old" SNC, a solution of SNC prepared 2-7 days earlier and from 
which the gaseous nitric oxide had dissipated. This control tested whether the cystine 
derivative or other stable by-products could be responsible for any effect on palmitate 
incorporation. After treatment, proteins were immunoprecipitated with antibodies and 
separated by SDS-PAGE. Proteins were transferred to a PVDF membrane and radio-labeled 
proteins were detected by fiuorography. 
The effect of 4 mM SNC on the palmitoylation of transferrin receptor and caveolin is a 
decrease in palmitate incorporation (Fig. lA and IB). In contrast, palmitate replacement on 
H-Ras is increased upon SNC treatment. The results indicate that SNC causes differential 
effects in palmitate incorporation of proteins in NIH 3T3 cells. SNC seems to specifically 
increase the palmitoylation of WT H-Ras, even while causing a general decrease in palmitate 
incorporation in other proteins. 
SNC increases H-Ras palmitate incorporation in a dose and time dependent manner 
To ftirther characterize the effect of SNC, WT H-Ras NIH 3T3 cells were labeled with 
[^H] palmitate and simultaneously treated with different concentrations of SNC. Results 
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from two experiments indicated that palmitate incorporation is unaffected by micromolar 
amounts of SNC (Fig. 2). The SNC effect on the pahnitoylation of H-Ras begins only around 
2 mM and then smoothly rises to 4 mM. Previous uses of SNC by others have been in the 
micromolar amounts. However, the treatments have always been without serum. We have 
included serum in our media during SNC treatment because it contains growth factors 
affecting Ras-GTP binding, and better replicates in vivo conditions. Concentration above 4 
mM were not studied because cellular adhesion is lost within approximately 30 minutes at 
higher concentrations. A SNC concentration of 4 mM is not toxic, as replacement of SNC-
containing media with growth media allows cells to grow normally (data not shown). Nitric 
oxide can cause different effects in low versus high concentrations. The results show that low 
concentrations of SNC do not seem to affect, by either increasing or decreasing, palmitate 
replacement on H-Ras. Additionally, the data suggests that SNC can be used most 
effectively at 4 mM to induce the increased palmitate incorporation into H-Ras. 
To determine whether SNC also acted in a time-dependent way, WT H-Ras NIH 3T3 
fibroblasts were again labeled in the presence of 4 mM SNC. Cells were lysed at times 
between 15 minutes and 2 hours and WT H-Ras immunoprecipitated. Times greater than 
two hours were not studied because loss of cell adhesion was observed. Again, this SNC 
effect on cell adhesion is not toxic, as replacement of media containing SNC with media alone 
at 2 hr allowed cells to remain adherent and continue to grow (data not shown). The results 
showed that SNC increases H-Ras palmitoylation rapidly, almost doubling the palmitate 
incorporated within 15 minutes (Fig. 3A). Results of two additional experiments showed 
similar resuUs: SNC treatment increased palmitate incorporation quickly (< 30 minutes) and 
sustained the increase for more than an hour. After one hour, the SNC-induced increase in 
palmitate incorporation over controls diminished, until control samples and SNC-treated 
samples showed equal amounts of [^H]palmitate incorporated. The nitrosothiol effect on the 
palmitoylation of WT H-Ras is rapid. SNC is acting in a dose and time-dependent manner to 
increase the palmitate incorporation of WT H-Ras. 
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A mutated, activated H-Ras (v-H-Ras) has been identified in a retrovirus and has slightly 
different palmitoylation/depalmitoylation rates than WT H-Ras (TLB, JEB manuscript in 
preparation). To find out if SNC would also alter the palmitate incorporation into this 
mutant v-H-Ras, stably transfected R12VT59 Ras NIH 3T3 cells were labeled in the 
presence of 4 mM SNC. The v-H-Ras was immunoprecipitated, and detected by 
fluorography (Fig. 3B). Six additional experiments showed similar results. From the 
representative fluorograph, SNC increased the [^H] palmitate incorporated into the v-H-Ras 
protein. The graph shows that this increase over controls was rapid, doubling the [^H] 
palmitate incorporated within 15 minutes. Like in the WT-H-Ras, the effect was somewhat 
transient as the difference between control and SNC treated v-H-Ras palmitoylation 
decreased after at approximately an hour. Experiments with v-H-Ras did not continue after an 
hour because these transformed cells lost adherence at approximately 1.5 hours. Thus, SNC 
was effective in increasing the palmitoylation of both WT H-Ras and activated v-H-Ras. 
SNC increases depalmitoylation of H-Ras 
The previous assay was designed to measure palmitate replacement. To increase 
replacement, it is assumed that palmitate removal must also be stimulated. The results of the 
simultaneous palmitate labeling and SNC treatment indicated that the deacylation of H-Ras 
might be increased, as the SNC-induced increase in [^H] palmitate labeled H-Ras seemed to 
peak before 2 hr., and then decreased. To assess in a more direct way if palmitate removal 
was affected by SNC, pulse/chase techniques were used. 
To test this, WT H-Ras and v-H-Ras stably transfected cells were labeled with [^H] 
palmitate, then chased with media containing an excess of non-radioactive palmitate for times 
between 30 min. and 2 hr. H-Ras was immunoprecipitated and separated by SDS-PAGE. 
The area on the resulting fluorograph were measured and the values then graphed using Prism 
Graphpad. The data best fits a double exponential decay. A single exponential did not fit the 
data points, as its R^ value was smaller than that of the best fit double exponential. A double 
exponential line indicates two half-lives of depalmitoylation. It is unknown why the 
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palmitate has two half-lives, but may be due to the two sites of palmitate addition on H-Ras. 
Additionally, H-Ras has been observed in and out of microdomains on the plasma membrane. 
If H-Ras is more accessible to a deacylase from one of these locations, palmitate turnover 
would be expected to be faster than if the protein was not available to a palmitoyl-
thioesterase. Previous studies have not analyzed palmitate turnover at this level of detail. 
From the graphs, SNC causes a rapid and sustained increase in the deacylation of both 
WT and v-H-Ras. For WT-H-Ras, SNC increases the depalmitoylation rate by 
approximately 7 times, and the rate of deacylation of v-H-Ras is increased by approximately 
4 times during SNC treatment. Combined with our finding that SNC also increases the 
palmitate replacement on H-Ras, we suggest that the over-all palmitate turnover of H-Ras is 
significantly increased by this nitroso-thiol. 
SNC is not modifying H-Ras by activating guanylate cyclase or nitrosylating Cys 118 
A well-known mechanism of nitric oxide mediated effects is an increase in guanylyl 
cyclase activity, which in turn increases amounts of cellular cGMP (40). To analyze whether 
the increased palmitate turnover of H-Ras was mediated by cGMP, we labeled v-H-Ras 
transfected NIH 3T3 cells with [^H] palmitate and simultaneously treated cells with 8-Br-
cGMP, a membrane-diffusible cGMP analog. No detectable change on palmitate 
incorporation was detected in cells treated with 8-Br-cGMP over a 2 hr. time course in two 
experiments, indicating that the palmitate turnover on H-Ras is increased by SNC 
independently of cGMP (data not shown). This implies that the observed increase in 
palmitate turnover caused by SNC occurs independently of possible effects of SNC on 
guanylyl cyclase. 
Others have recently shown that H-Ras is a target of oxidants and nitric oxide-releasing 
agents. During treatment of Jurkat, a T cell lymphoma cell line, with NO gas, the percentage 
of Ras bound to GTP increases, indicating that NO may trigger an increase in Ras activity 
(31,32). Researchers have hypothesized that cysteine 118 in the GTP-binding pocket of H-
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Ras is targeted by NO or its metabolites, and is nitrosylated (33). C118S H-Ras mutants in 
vitro are immune to nitric oxide-induced activation (41). 
Using this same 118S mutant expressed in NIH 3T3 cells, we determined that the 
nitrosylation of C118 is not the cause of the increased palmitate tumover. Again, pulse-
labeling and pulse-chase experiments were performed using C118S H-Ras transfected NIH 
3T3 cells. The SNC-treated 118S H-Ras cells showed an increase in [^H] palmitate 
replacement at a rate 4 times faster than controls, which is almost identical to the increase 
observed in SNC treated WT H-Ras cells (Fig. 5A). Additionally, the deacylation rate of 
118S was also increased by SNC treatment (Fig. 5B). Therefore, SNC nitrosothiol is not 
increasing palmitate tumover by targeting 118C within the GTP-binding pocket of H-Ras for 
nitrosylation or any other nitric oxide reaction. 
H-Ras activity is decreased during SNC treatment 
While establishing that SNC increases the tumover of the palmitate on H-Ras, it was 
unknown how this change on the C terminus would affect the overall activity of the protein. 
SNC was able to increase the palmitate tumover within minutes and may have been 
simultaneously affecting H-Ras signaling. To determine if a SNC-induced increased rate of 
palmitoylation/ depalmitoylation at the H-Ras carboxy- terminus would affect its activity, 
we monitored its GTP binding and its signaling through Erk kinase. 
118S, WT, and v-H-Ras stably transfected NIH 3T3 cells were labeled with an excess of 
[^^P] inorganic phosphate after a 12 hour 1% semm-depletion. Cells were then treated with 
NO-depleted SNC as a control and fresh SNC for 30 minutes. The H-Ras was 
immunoprecipitated and GTP and GDP separated by thin layer chromatography. After 
fluorography, the GTP and GDP that had been bound to Ras were observed and quantified. 
In 118S and WT H-Ras cells, a slight decrease of Ras in the GTP-bound form was observed. 
Initial percent GTP in these non-activated H-Ras proteins was so low that differences 
between control and SNC-treated samples were difficult to measure. However, SNC did not 
increase the percentage of GTP in these samples in NIH 3T3 fibroblasts. In three separate 
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experiments with v-H-Ras, SNC obviously decreased the amount of H-Ras bound to GTP, 
from 59% to 19% (Fig. 6). Similarly to the dose dependency of the SNC effect on palmitate 
replacement on H-Ras, a SNC dose-response experiment measuring nucleotide-binding was 
conducted that showed SNC began to decrease GTP binding to H-Ras at concentrations 
between 2 and 4 mM (data not shown). An increase in GTP-binding during SNC treatment 
was not observed. These results indicate that S-nitrosocysteine is able to decrease the 
amount of mutationally activated v-H-Ras in the GTP-bound state. Within the short time 
that it simultaneously increases palmitate turnover, SNC is most likely decreasing Ras 
signaling, 
Because SNC affected the C terminal modifications and the GTP-binding of H-Ras, we 
hypothesized that Ras signaling would also be decreased by the nitrosothiol. Ras binds to 
Raf, a normally cytosolic kinase, and transfers it to the plasma membrane. This activates a 
series of cytosolic kinases each, in turn, activated by phosphorylation. Two of these cellular 
kinases, Erk 1 and Erk 2, are several kinases downstream of H-Ras. Erk activation can be 
monitored easily because the activated, phosphorylated forms of murine Erk 1 and Erk 2 have 
a slightly slower mobility than the unphosphorylated forms on 12.5% SDS-PAGE gels and 
can be observed by immunoblotting. 
Stably transfected WT H-Ras NIH 3T3 cells were serum-starved to deactivate the Ras 
pathway and, therefore, the Erks. Cells were stimulated with serum either in the presence of 
nitric oxide-depleted 4 mM SNC or freshly made 4 mM SNC. Cells were then lysed and 
cellular proteins separated by SDS-PAGE. Phosphorylated and non-phosphorylated Erk 1 
and Erk 2 were observed using an Erk antibody (Fig. 7). The appearance of additional bands 
recognized by the Erk antibody upon serum-stimulation indicated that Erk was being 
phosphorylated. SNC was able to decrease the phosphorylated Erks during a short treatment 
indicating that over-all Ras pathway signaling is being decreased. This effect was transient, as 
the ability of Erk to be activated was regained after the S-nitrosocysteine in the media had 
been depleted over 2 hr. Again, the results of a dose-response experiment showed that the 
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inhibition of a 10% serum-stimulation of Erk 1 and Erk 2 by SNC occurs only between 2-4 
mM (data not shown). 
While the loss of phosphorylation of Erks could be a result of decreased H-Ras activity, 
the possibility that SNC was increasing phosphatase activity responsible for deactivating 
Erks existed. We repeated the Erk experiments above, but used vanadate as a phosphatase 
inhibitor. If SNC was activating Erk phosphatases, then vanadate would inhibit this 
activation. If however, the decreased phosphorylation of Erks during SNC treatment was 
caused upstream by H-Ras inactivation, then vanadate would not have an effect. Erk 
remained phosphorylated in vanadate-treated samples, even during starvation (Fig. 7B). In 
SNC-treated lanes, Erk phosphorylation is eliminated, except when in the presence of 
vanadate. SNC-treatment did not completley eliminate phosphorylated Erk in vanadate-
treated samples. Similar results were observed in multiple experiments (n>5). This suggests 
that the Erk deactivation observed during SNC treatment may be the result of increased 
phosphatase activity, rather than inactivation of the upstream H-Ras. 
Multiple oxidants increase palmitate incorporation on H-Ras 
Nitric oxide has many cellular metabolites. In the previous experiments, S-
nitrosocysteine, a nitrosothiol, was used to affect the palmitoylation of H-Ras. It was 
possible that other oxidants could cause similar increases in palmitate tumover on H-Ras. To 
test this, WT transfected NIH 3T3 cells were labeled for 30' with [^H] palmitate in the 
presence of various oxidants: SNC; S-nitrosoglutathione, a slightly larger MW nitrosothiol 
than S-nitrosocysteine; SIN-1, a compound that generates peroxynitrite (ONOO-); hydrogen 
peroxide; andNOC-18, a nitric oxide radical producer. WT H-Ras was immunoprecipitated 
with a monoclonal antibody and observed by fluorography. The graph in Fig. 8 shows the 
effects of these oxidants on the rate of palmitate replacement on H-Ras. The H-Ras isolated 
from cells treated with control media or medium containing old SNC incorporated 
approximately equal amounts of [^H] palmitate. This showed that the cystine or other 
breakdown by-products of S-nitrosocysteine present in the old SNC solution was not causing 
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any effects on palmitate incorporation into proteins. However, simultaneous [^H] palmitate 
labeling and treatment with 4 mM SNC increased the amount of palmitate incorporated 
approximately four-fold. An approximate 1.5 to 2-fold increase in palmitate incorporation 
occurred with the oxidants SNOG, SIN-1, and H2O2. These results concur with the 
observation that SNC increases palmitate replacement on H-Ras. Additionally, it seems H-
Ras palmitate replacement on H-Ras increases after other oxidant treatments, though to a 
slightly lesser degree. However, this does not indicate that all oxidants affect the 
palmitoylation of H-Ras: NOC-18, a nitric oxide radical producer, only increased the 
palmitate incorporation by less than 20% which might be insignificant. Additionally, we 
used the oxidants NOC-15, a nitric oxide radical producer, and SNAP, a large molecular 
weight nitrosothiol, as treatments in [^H] palmitate pulse-chase experiments and did not 
observe any affect of these oxidants on the depalmitoylaiton of H-Ras (data not shown). 
DISCUSSION 
Using NIH 3T3 cells stably transfected with H-Ras and its mutants, we have shown that 
the nitric oxide producer, S-nitrosocysteine, and other oxidants, increase the palmitate 
turnover of H-Ras within minutes. This effect is observed in WT, as well as an activated v-
H-Ras mutant. While this nitrosothiol increases the deacylation cycle of H-Ras, this seems 
to be somewhat specific to this protein, as most other proteins show a slower rate of 
palmitate replacement during SNC treatment. While SNC increases the palmitate turnover on 
H-Ras, it simultaneously shows effects on the activation of the Ras signaling pathway, 
including a decrease in GTP-binding of an activated v-H-Ras, as well as decreased Erk 
phosphorylation. 
The S-nitrosocysteine nitrosothiol specifically targets H-Ras in NIH 3T3 fibroblasts 
Simultaneous [^H] palmitate labeling and some oxidant treatments led to an increase in 
palmitate replacement on H-Ras. However, results showed that palmitate replacement on H-
Ras was increased by treatment with only some oxidants, such as the small molecular weight 
nitrosothiols, S-nitrosocysteine, and S-nitrosoglutathione; the peroxynitrite producer, SIN-l; 
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and hydrogen peroxide. SNAP, a large molecular weight nitrosothiol; and NOC-15 and NOC-
18, nitric oxide producers, caused no increases in palmitate replacement on H-Ras. Of the 
oxidants that do increase palmitate replacement on H-Ras, SNC seems to cause the greatest 
increase. Below, we offer a model to explain why the smaller molecular weight SNC caused 
such a significant change in palmitoylation of H-Ras compared to the other oxidants. 
The specificity of S-nitrosocysteine to cause a greater response compared to other 
oxidants may be due to the nitrosothiol's ability to enter cells and come into contact with 
target proteins. S-nitrosocysteine, as a small modified amino acid, is able to pass through the 
plasma membrane through L-type-like amino acid transporters. Studying neurotransmitter 
regulation in rat hippocampus, Satoh et al. (42) found that SNC increased noradrenaline 
release independently of cGMP. This effect was inhibited by other L-type amino acids and a 
specific inhibitor of the L-type amino acid transporter, indicating that exogenous treatment of 
SNC causes an effect by entering the cells as a nitrosothiol through the L-type amino acid 
transporter. The specificity of SNC to cause different changes in the palmitoylation of a 
variety proteins in fibroblasts may also be due to the ability of SNC to cross the plasma 
membrane through a transporter that is unable to carry the other nitrosothiols used (SNG and 
SNAP). 
If the changes to palmitate incorporation of proteins require the SNC nitrosothiol to 
cross the membrane, then we can assume that the nitrosothiol is important to the effect, in 
contrast to breakdown products, nitric oxide and cystine. Nitric oxide rapidly diffuses across 
hydrophobic membranes. The nitric oxide donor, NOC-15, produces nitric oxide gas at a rate 
similar to the amount synthesized by SNC. If the nitric oxide radical was responsible for the 
changes in palmitoylation we observed, then we would expect that NOC-15 would mimic the 
effect seen with SNC. Instead, we observed no change in palmitate incorporation with the 
nitric oxide donor, NOC-15. In addition, the SNC breakdown product, cystine, was not 
responsible for the palmitoylation effect, as treatment with nitric oxide-depleted SNC 
solution did not change the palmitoylation of proteins. In fact, the old SNC was used as 
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control. So, we hypothesize that L-S-nitrosocysteine acts independently of the nitric oxide it 
produces. 
Therefore, our results indicate that S-nitrosocysteine is causing changes in palmitoylation 
through nitrosylation, or transfer of covalently attached nitrogen oxide, of the palmitoylated 
protein cysteine or acylation/deacylation machinery. SNC acts as a nitrosothiol, independent 
of the nitric oxide radical. Research by others has suggested that many of the effects 
attributed to nitric oxide may actually be caused by the nitrosothiol metabolic products. 
Most of these effects are cGMP independent, as is the effect we observe on the 
palmitoylation of proteins. It has been suggested that nitrosothiols may react specifically 
with available stereo-specific cysteine on proteins. Stamler et al. (43) has reported that 
nitrosothiols attack a target cysteine on the iron binding domain of hemoglobin. Others have 
observed the specific effects of SNC on the cardiovascular system in rats when it is injected 
into the nucleus tractus solitarii of the brain. This treatment caused a decrease in heart rate 
and arterial pressure in the rat (44). Other nitric oxide donors and nitrosothiols were unable 
to illicit any response when injected. Using the D-S-nitrosocysteine isomer of the normal L-
S-nitrosocysteine to produce equal amounts of released nitric oxide, no effect was observed. 
The authors hypothesized that only a stereo-specific conformation of nitrosothiol could 
attack a target cysteine in a protein pocket (45,46). It may be that SNC is acting stereo-
specifically to attack a cysteine either on the Ras and other protein's themselves, or the 
acylation/deacylation machinery. This would explain the different palmitate effects of SNC 
on various proteins. We suggest that the palmitoylated cysteines of proteins may be in 
various conformations that are more or less accessible to the nitrosothiol, allowing SNC to 
have diverse effects on the palmitate replacement of proteins. 
The palmitoylation of H-Ras is significantly affected by SNC treatment. SNC is able to 
increase the over-all palmitate tumover of H-Ras. We can hypothesize that SNC is acting as 
a nitrosothiol and that the nitric oxide gas released may not be the causative agent in 
increasing tumover. If this is true, then we can presume that SNC is directly transferring the 
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nitrogen oxide attached to it to either H-Ras or the acylation/deacylation enzymes. This 
would be a direct nitrosylation of H-Ras or the enzymes by the active nitrosothiol. 
If H-Ras is targeted by SNC, we can attempt to select which cysteine is targeted. Lander 
et al. reported that a truncated H-Ras was able to be nitrosylated. Mass spectrophotometry 
experiments showed that the specific cysteine nitrosylated was in the GTP-binding pocket at 
residue 118 (33). Mott et al. went on to show that the CI 18S H-Ras mutant was no longer 
nitrosylated (41). Our results using a full length C118S H-Ras mutant in NIH 3T3 
fibroblasts show that increased palmitate turnover caused by SNC is not affected without the 
cysteine in that position. In addition, we did not see the reported increase in GTP-binding 
described by Lander, et. al. in these experiments. This may be due to cell specificity of the 
SNC effect, as their results came from Jurkat cells and ours from NIH 3T3 cells. This does 
not mean that 118C is not being nitrosylated in our experiments, only that this cysteine's 
nitrosylation is not required for increased palmitate turnover. 
The more likely cysteine targets on H-Ras are at positions 181, 184, and 186. Because 
186C is stab! Jified with isoprenoid co-translationally, we can eliminate it as a 
nitrosylation target causing the palmitoylation effects. Instead, we suggest if H-Ras is being 
modified by the nitrosothiol, SNC is nitrosylating either or both of the palmitoylation sites at 
181C and 184C. It may be possible to discern which, if either, of the cysteines is 
nitrosylated using CI8IS or C184S mutants. However, it has been reported that these 
mutants themselves have modified palmitate turnover rates, so appropriate controls need to 
be included (47). 
The other possibility is that cysteines on acylation or deacylation machinery are being 
nitrosylated. We cannot speculate on this as the enzymes have not yet been defined. Once 
the acyl-transferase and deacylases have been identified and purified, future experiments 
could test whether any available cysteines are possibly nitrosylated during SNC treatment. 
Because the palmitate incorporation of many proteins is affected by SNC treatment, this may 
be a possible model of the SNC effect. 
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Ras signaling is hindered by SNC treatment 
We have shown that H-Ras activity and pathway signaling in NIH 3T3 cells is inhibited 
upon SNC treatment. GTP binding of activated H-Ras is decreased. This, in turn, possibly 
inhibits further signaling through the Ras-Raf pathway. Evidence for this is the decrease in 
Erk phosphorylation, and thus activation, with SNC treatment. However, this effect may 
not be due to inhibition of signaling upstream at H-Ras. Instead, SNC may be activating 
phosphatases to deactivate Erks. This would be a unique action of SNC. Previous work by 
others has shown that nitric oxide producers can inhibit certain phosphatases, not activate 
them (48). Regardless of method, H-Ras activity and pathway signaling are decreased in NIH 
3T3 cells during SNC treatment. 
Proposed relationship between H-Ras palmitoylation and activation 
While our results show that SNC increases the palmitate tumover of H-Ras and 
simultaneously decreases H-Ras GTP binding, it is not possible to draw the conclusion that 
these two events are interdependent. In fact, because of the promiscuity of NO with various 
chemical targets including metals, oxides and sulfurs, it is possible that the effects on H-Ras 
by SNC are mediated independently of one another: SNC as a nitrosothiol attacks the 
palmitate target cysteines of H-Ras or acylation/deacylation enzymes; SNC, either as an 
active nitrosothiol or nitric oxide radical producer, decreases GTP binding of H-Ras. Several 
tests could be performed to attempt to find one effect by SNC without the other. 
However, another possible model is that SNC increases H-Ras palmitate tumover, which 
in turn causes a secondary effect, the decrease of GTP binding. This would indicate a direct 
relationship between palmitate cycling on H-Ras and the activation state of the protein. 
Previous studies of other proteins have suggested that this relationship between palmitate 
modification and activation state is utilized. Treatment of cells with the agonist isoprotemol 
increases GTP-binding of Gs^ and significantly increases the palmitate tumover of the 
protein. The authors suggested that the conformation change that occurs when GTP binds 
the a sub-unit of Gs allows the two other sub-units, P and 7, to be released. This then allows 
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the Gs„'s palmitoylated cysteine to be presented to a deacylase, which can then cleave the 
thioester bond, increasing palmitate turnover. While the protein is briefly unpalmitoylated, 
its GTPase hydrolyzes the GTP to GDP, inactivating the protein. Gs„ is palmitoylated and 
binds again to Py (18,20). 
H-Ras is closely related to the Ga sub-units of the trimeric G proteins. Based on the 
previously suggested model, if SNC increases the palmitate turnover of H-Ras, perhaps the 
rate of GTP hydrolysis is also increased. This would explain our observation of decreased 
GTP-bound H-Ras during SNC treatment. A model based on the opposite assumption is 
that the conformation change upon GTP hydrolysis in some way increases the palmitate 
turnover of H-Ras. Perhaps the conformational change that occurs upon GDP binding of H-
Ras allows the C terminus of the protein to be more available to deacylases. 
In this study, we cannot suggest that palmitate turnover and activation state of H-Ras 
are inter-related. However, we have shown that SNC, used as a tool, can increase the 
palmitate turnover of H-Ras. This is the first reported example of an agent that could in 
some way affect the palmitoylation of H-Ras. The results indicate that the palmitate 
modifications of H-Ras may be cellularly regulated by endogenously synthesized 
nitrosothiols. Because SNC can increase the H-Ras palmitate turnover, perhaps other 
unidentified cellular products may also. We suggest that H-Ras palmitoylation is a 
regulatable event and that SNC may be used as a tool to further study the effects of its 
regulation. 
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FIGURE LEGENDS 
Fig. 1. S-nitrosocysteine has differing effects on the palmitate incorporation of 
three specific proteins. WT NIH 3T3 cells were labeled with [^H] palmitate and 
simultaneously treated with 4 mM SNC for 1 hour. (A) Transferrin receptor was 
immunoprecipitated using a polyclonal antibody (Zymed). (B) Caveolin was 
immunoprecipitated with a rabbit polyclonal antibody. {C) WT H-Ras was 
immunoprecipitated with 146-3E4 monoclonal mouse antibody. The proteins were separated 
by SDS-PAGE and transferred to PVDF membranes. The membranes were prepared for 
fluorography and put on film for 8-135 days at -70 C. (D) The [^H] palmitate protein bands 
were quantified with ImageQuant and graphed. The solid black bars are control samples and 
the gray bars SNC treated samples. 
Fig. 2. SNC increases palmitate incorporation of H-Ras in a dose dependent 
manner. (A) WT NIH 3T3 cells were labeled for 30 minutes with 1 mCi [^H] palmitate and 
simultaneously treated with concentrations of SNC between 0-4 mM. H-Ras was 
immunoprecipitated and separated by SDS-PAGE. Proteins were transferred to PVDF 
membranes and sprayed with En^Hance. Membranes were exposed to film at -70 C for 9 
days. (B) The membrane was developed by Western blotting with 146-4E and the [^H] 
palmitate bands normalized to the amount of protein on the membrane. The graph shows the 
increase of palmitate incorporation of H-Ras over the 0 mM SNC control as the SNC 
concentration increases. 
Fig. 3. SNC increases palmitate incorporation into WT and v-H-Ras in a time-
dependent manner. (A) WT or (B) v-H-Ras (R12T59) stably transfected NIH 3T3 cells 
were pulse-labeled with 1 mCi [^H] palmitate for 15-120 minutes. Cells were simultaneously 
treated with 4 mM SNC which was added every 30 minutes. H-Ras was immunoprecipitated 
with 146-3E4 antibody and proteins separated by SDS-PAGE. Proteins were transferred to 
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PVDF membranes and prepared for fluorography. Membranes were put on film for 6-14 
days. The [^H] palmitate bands were normalized to protein amounts after immunoblotting of 
the membrane was performed with 146-3E4 antibody. The black line and diamonds indicate 
the control treated samples. SNC treated samples are represented by the gray line and 
squares. Results fi"om 3 additional WT and 6 additional v-H-Ras pulse-label experiments 
showed similar results. 
Fig. 4. SNC increases the palmitate turnover of WT and v-H-Ras. ( A )  WT or ( B )  v-
H-Ras (R12T59) stably transfected NIH 3T3 cells were pulse-labeled with 1 mCi [^H] 
palmitate for 3 hr, then chased with media containing 200 |J,M palmitate for times indicated. 
Cells were treated with 4 mM SNC every 30 minutes during the chase period. H-Ras was 
immunoprecipitated and separated by SDS-PAGE. Proteins were transferred to PVDF and 
the membranes were sprayed with En^Hance. The membranes were exposed to fihn for 13-
56 days at -70 C. [^H] palmitate bands were normalized to protein bands developed after 
Western blotting. The WT and v-H-Ras normalized measurements were then plotted. A best 
fit double exponential line was constructed using the computer program Graphpad Prism. 
The solid black line and squares represent the control samples and the gray line and triangles 
represent SNC treated samples. The graph is a composite of three WT experiments and two 
v-H-Ras experiments. The phosphorylated v-H-Ras protein measurements were not included 
in these graphs. However, SNC caused a similar increase in palmitate turnover on this 
protein. Results of additional experiments using 2 mM SNC on both protein cell lines were 
not included, but show the same trend of increased palmitate turnover in SNC treated 
samples. 
Fig. 5. SNC is not increasing palmitate turnover of H-Ras by nitrosylation of 
118C. (A) C118S mutant H-Ras stably transfected NIH 3T3 cells were labeled with 1 mCi 
[^H] palmitate alone, or treated with nitric oxide-depleted 4 mM SNC or freshly made 4 mM 
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SNC for the times indicated. SNC was added every 30 minutes. {B)  The eel! line was pulse-
labeled with 1 mCi [^H] palmitate and chased with media containing 200 ^iM palmitate and 
either 4mM nitric oxide-depleted SNC or freshly made SNC. SNC was added every 30 min. 
In both experiments, the mutant H-Ras was immunoprecipitated and separated by SDS-
PAGE. Proteins were transferred to PVDF membranes and prepared for fluorography. 
Membranes were exposed to film for (A) 19 days and (B) 13 days at -70 C. The [^H] 
palmitate bands were quantified using ImageQuant and normalized to protein amounts 
measured on the membrane after Western blotting. (A) The data from the labeling experiment 
was plotted: the hatched black line and diamonds signify labeling alone; NO-depleted SNC is 
represented by solid black line and squares; and the SNC treated samples are designated by 
the gray line and triangles. (B) The data from the pulse-chase were plotted and a best fit 
double exponential line was constructed using Graphpad Prism. The solid black line and 
squares represents the NO-depleted SNC treated samples and the gray line and triangles 
signify the SNC treated samples. 
Fig. 6. SNC decreases H-Ras GTP-binding. (A) 118S, WT, and v-H-Ras stably 
transfected NIH 3T3 cells were labeled with 0.5-1 mCi [^^P] inorganic phosphate for 4 h after 
a 1% serum-starvation over-night. Either 4 mM NO-depleted SNC or 4 mM freshly made 
SNC was added for 30 min. H-Ras proteins were immunoprecipitated with 146-3E4 
antibody. H-Ras was spotted on polyethyleneimine cellulose plates and guanine nucleotides 
separated with 0.75 M KH2PO4 (pH 3.4). Plates were dried and exposed to film at -70 C for 
10-31 days. (B) GTP and GDP amounts were quantified using ImageQuant. Percentages of 
GTP were calculated for each sample. The graph represents one sample for 118S, the average 
of 2 WT experiments, and the average of 3 v-H-Ras experiments. Black columns represent the 
control samples and gray columns the SNC-treated samples. 
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Fig 7. SNC transiently inhibits tiie serum-stimulated piiosphoryiation of Erk. (A) 
WT H-Ras stably transfected NIH 3T3 cells were incubated in serum-depleted media for 2 
hr. Starvation media was replaced with media containing 10% serum and either 4 mM old 
SNC or 4 mM fresh SNC. Every 30 min., additional fresh SNC was added to one set of 
sample plates. No additional SNC was added to control or the single addition SNC sample 
plates. Cells were lysed in IX sample buffer at the times indicated. Proteins were separated 
by SDS-PAGE and transferred to PVDF membranes. After blocking in milk, Erk proteins 
were detected by Westem-blotting using an Erk 1 antibody, which detects both Erk 1 and Erk 
2 in un-phosphorylated and phosphoiylated forms. (B) WT H-Ras stably transfected NIH 
3T3 cells were incubated in serum-depleted media for 2 hr. Some samples had vanadate, a 
phophatase inhibitor, added after 1 hr of starvation. Starvation media was replaced with 
media containing 10% serum and either 4 mM old SNC or 4 mM fresh SNC for 30 min. 
Vanadate was included in the treatment media in samples indicated in figure. 
Fig. 8. Oxidant-specific effects on the rate of palmitate replacement in WT H-Ras. 
(A) WT H-Ras stably transfected NIH 3T3 cells were labeled for 30 min. with 1 mCi [^H] 
palmitate in the media containing no additions, nitric oxide-depleted 4 mM SNC, fresh 4 mM 
SNC, 4 mM SNG, 2 mM SIN-1, 100 |iM H2O2 or 200 |iM H2O2. H-Ras was 
immunoprecipitated using 146-4E antibody. Proteins were separated by SDS-PAGE and 
transferred to PVDF membrane. The membrane was sprayed with En^Hance and put on film 
for 17 days at -70 C. After fluorography, the [^H] palmitate signal was normalized to the 
amount of protein present by measuring H-Ras on the membrane by Western blotting using 
the 146-4E antibody. (5) The normalized amounts of [^H] palmitate were measured after 
scanning using ImageQuant. The graph represents the effects of various oxidants on the 
palmitate incorporation into WT H-Ras. 
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CHAPTER 3: ACCELERATED PALMITATE TURNOVER IN ACTIVATED 
FORMS OF H-RAS INDICATES THAT THE H-RAS C-TERMEVUS 
RESPONDS TO GTP BINDING 
A paper prepared for submission to Journal of Biological Chemistry 
Tara L. Baker and Janice E. Buss 
ABSTRACT 
The small GTPase, H-Ras, is active in a GTP-bound conformation and sends signals 
through several cell pathways. When the GTP is hydrolyzed, the GDP-bound H-Ras is 
inactive and unable to bind to effectors. For normal signaling, H-Ras must be localized to the 
plasma membrane. It is able to associate with the hydrophobic surface of the membrane by 
it's C terminal lipid modifications. H-Ras is stably modified with the addition of an 
isoprenoid at its terminal 186 cysteine. At cysteines in positions 181 and 184, palmitate is 
added through ' thio-ester bonds. The palmitoylation of H-Ras has been suggested to be 
required for mc: lane targeting and association. As H-Ras must be at the membrane for 
signaling, palmitate is required for proper functioning. Understanding the reversible palmitate 
modification may lead to information about H-Ras function and regulation. Using [^H] 
palmitate pulse-chase experiments, we have measured the palmitate turnover rates for wild-
type H-Ras (WT), N17 dominant negative H-Ras (N17), 61L H-Ras (61L) and v-H-Ras 
transfected in NIH 3T3 fibroblasts. All H-Ras proteins studies gave data that suggested 
palmitate was being replaced at two different rates, one slow (>10 hr) and one fast (39 min. 
to 2.7 hr). Pulse-chase data from a singly palmitoylated H-Ras (18IS) indicated that a single 
palmitate on an H-Ras protein has a much faster palmitate turnover rate than when another 
lipid is near-by. In addition, we have found that the faster palmitate turnover rate on 
activated, or primarily GTP-bound, H-Ras proteins transfected in NIH 3T3 fibroblasts is 
increased compared to palmitate tumover on WT and dominant negative H-Ras proteins. 
The population of 61L and v-H-Ras proteins in NIH 3T3 fibroblasts have a fast palmitate 
tumover between 0.9-1.5 hr, and WT and N17 palmitate half-lives range from 2.1-2.7 hr. 
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Using these measured half-lives and determined %GTP-bound H-Ras in the cell lines, we 
approximated the palmitate half-Hfe on a single H-Ras molecule. In a GTP-bound 
conformation, the palmitate on H-Ras may have a half-life less than 39 min. In a GDP-bound 
conformation, palmitate half-life on H-Ras could be up to 3 hr. Our data suggests that 
activation of H-Ras could increase palmitate turnover by up to 4.6 times. Our data also 
suggests that activated H-Ras in NIH 3T3 fibroblasts have an increased palmitate turnover 
when compared to WT and N17 H-Ras transfected cells. 
INTRODUCTION 
Ras is a small GTPase that acts as a molecular switch in several cell signaling pathways. 
When bound to GDP, the protein is in an inactive conformation and unable to bind to target 
proteins. Upon GTP binding, the protein is "on" and able to bind to its effector proteins. 
The change in conformation upon GTP binding is significant and allows an effector domain of 
Ras to interact with proteins, such as Raf kinase and GAP (GTPase activating protein)(l). A 
signal is then sent through a kinase cascade to the nucleus, where gene expression is regulated. 
The conformational changes that occur upon GTP binding have been observed using x-
ray crystallography and NMR. Current structural models of Ras describe a Switch I domain 
between amino acid residues -30-42, centered on residues 33 and 35. When GTP binds in an 
inner pocket of Ras, two amino acids within this Switch I domain. Asp 33 and Thr 35, under­
go a 180 degree conformational change and become accessible to negative regulators and 
effector proteins (1,2). Raf kinase is one of these effectors. The Ras binding domain (RBD) 
of Raf recognizes Asp 33 and Thr 35 of Ras only when Ras is in a GTP bound conformation. 
An additional Switch II region of Ras has been described that also changes conformation upon 
GTP binding. Again, Raf recognizes this change and further interacts with Ras. In this case 
however, the cysteine-rich or zinc finger domain of Raf interacts with the amino acids Glu 60 
and Tyr 64 in the Switch II domain of Ras(3-5). 
Recent evidence has indicated that the membrane binding domain of Ras may also play a 
role in efficient Ras-Raf interaction. The C terminus of Ras is lipid modified to increase 
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membrane binding affinity. These lipids are necessary for Ras membrane targeting and 
binding. All four types of mammalian Ras, H-Ras, N-Ras, K4A and K4B-Ras are lipid 
modified at their C terminus with a 15 carbon isoprenoid(6). Each Ras protein has a CaaX 
(where "C" is cysteine, "a" is any aliphatic amino acid, and "X" any amino acid) sequence at 
its C terminus that is a signal sequence for a famesyltransferase. Famesyl is bound to the 
cysteine by a stable thioether bond, and the last three amino acids cleaved(7). The membrane 
affinity of Ras is then increased by either an upstream polybasic domain in K4B-Ras, or 
palmitoylation of one, in the case of N-Ras and K4A-Ras, or two near-by cysteines in H-
Ras(8,9). Results from Luo, et. al. suggest that normal processing of the C terminus of H-Ras 
is required for efficient Raf binding(lO). If the Raf zinc finger domain is added to 
unprocessed GTP-bound H-Ras protein in vitro, then Ras-Raf binding is abolished. This 
suggests that the membrane binding domain of H-Ras may be important for efficient effector 
binding. 
The membrane binding domain of another GTPase, Gaz, may also be important to 
interactions with its effector proteins and negative regulators. At the neuronal plasma 
membrane, Gaz interacts with and inhibits adenylyl cyclase when triggered by activation of 
the D2 dopamine receptor. Palmitoylation and myristoylation at the N terminus of Gaz is 
required for membrane association. If the site of palmitoylation is mutated (C3A), then the 
membrane binding of unpalmitoylated Gaz is disrupted. Additionally, adenylyl cyclase 
activity in CHO K1 cells transfected with the D2 dopamine receptor and C3A Gaz is 
enhanced upon D2 dopamine receptor activation(l 1). This suggests that palmitoylation of 
the membrane binding domain of Gaz may play a role in Gaz signaling by inhibiting its 
interactions with the adenylyl cyclase effector. Palmitoylation of the Gaz membrane binding 
domain has also been suggested to inhibit interactions with its negative regulator, Gz-
GAP(12). From these results, it could be hypothesized that the membrane binding domain of 
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this GTPase is involved in effector and negative regulator binding, thus playing a significant 
roleinGocz signaling. 
It is possible that the membrane binding domain of the H-Ras GTPase is important to 
effector and negative regulator binding. Raf and Ras-GAP bind to Ras in a GTP-dependent 
manner. Because the membrane binding domain of H-Ras is involved in Raf interactions, it 
might be possible that this C terminal region of H-Ras may also respond to activation upon 
GTP-binding. The crystallization of the C terminus of H-Ras has not yet been 
accomplished, so all structural models of H-Ras are of C terminal truncation mutants(l,2). 
However, Brandt-Rauf, et. al. used conformational energy analysis to predict the structure of 
the last 18 amino acids of the H-Ras C terminus (13). They then generated a computer model 
of a complete H-Ras molecule by integrating their predicted C terminus and the known 
crystal structure of the remainder of the protein. Their results suggest that the lowest energy 
conformation of the C terminus is a helix-bend-helix, and that this membrane binding domain 
is near-by the N terminus and Switch II region of H-Ras. From these results, it seems that 
the H-Ras membrane binding domain could in fact respond to conformational changes in the 
Switch II region upon activation by GTP binding. 
If GTP binding to H-Ras changes the conformation of the membrane binding domain, we 
then hypothesized that we could indirectly observe these changes using palmitoylation as a 
reporter. Palmitoylation of H-Ras is reversible. Acylation and deacylation rates can be 
measured using [^H] palmitate pulse-labeling and pulse-chase methods, respectively. We 
hypothesized that GTP related changes in the rates of palmitate turnover might be indicators 
of conformational changes in the membrane binding domain of H-Ras. To measure the effects 
of H-Ras activation on its C terminal palmitoylation, we compared the palmitate turnover 
rates on mutated H-Ras proteins that were bound primarily to either GDP or GTP. 
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METHODS 
Cell culture 
NIH3T3 cells stably transfected with 61L H-Ras, v-H-Ras (R12T59), 181S H-Ras (gift 
of B. Willumson), c-H-Ras (gift of L. Quilliam), and inducible N17 H-Ras (gift of A. 
Kazlauskas) were grown at 10% CO2 in Dulbecco's Modified Eagle's Medium supplemented 
with 10% calf serum (Hyclone). The N-17 H-Ras was induced by treatment with 50mM 
IPTGfor 16 hr. 
GTP/GDP Determination 
Protocol was performed as described in Satoh, et. al. and deVried-Smits, et. al (14,15). 
Confluent cultures of NIH 3T3 cells were grown over-night in 1% calf serum. Cells were 
then radiolabeled with 0.5-1 mCi [^^P] inorganic phosphate (NEN) for 4 h in phosphate-free 
media containing 1% calf serum. Cells were rinsed with PBS and lysed in GTP Lysis Buffer 
containing 50 mM Tris-HCl (pH 7.4), 20 mM MgCl2,150 mM NaCl, 0.5% (v/v) Nonidet P-
40, Aprotinin (20 mg/mL), 1 mM EOTA, and 1 mM Na3V04. Insoluble material was 
removed by centrifiigation at 750 g for 3 minutes. Supematants were cleared with 50% (v/v) 
BSA-coated charcoal in lysis buffer then H-Ras proteins captured by immunoprecipitation 
with either monoclonal antibody 146-3E4 (Quality Biotech) or Y13-259 (Calbiochem) using 
the GTP Lysis Buffer above. H-Ras and its bound nucleotides were eluted by heating to 60 
C for 5 minutes in a minimal volume of buffer containing 20 mM Tris-HCl (pH 7.4), 2 mM 
EDTA, 2% (w/v) SDS, 2 mM GDP, and 2 mM GTP. The eluants were cleared by 
centrifiigation at 10,000 g for 5' then samples were spotted on polyethyleneimine cellulose 
plates (J.T. Baker) and separated with 0.75 M KH2PO4 (pH 3.4). Guanylate nucleotide 
standards were visualized by UV detection and marked with a radioactive marker. Plates 
were dried and exposed to pre-flashed film using screen enhancers. GTP and GDP were 
measured by densitometry and the program ImageQuant. The percentage of GTP was 
calculated using the following equation: 
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%GTP= GTP {GDP X13) + GTP xlOO 
Radiolabeling and Immunoprecipitation 
Palmitate incorporation was measured by labeling confluent cells with 0.5-1 mCi 
[^H]palmitate (Dupont/NEN) in media containing non-essential amino acids , 20 mM Hepes, 
pH 7.2, 25 mg/mL cycloheximide and 10% calf serum(16). Labeling was stopped at times 
described by rinsing cells twice with Tris-buffered saline and lysing cells in a HI-SDS RIP A 
buffer (0.15M NaCl, 50 mM Tris (pH 7.0), 1% Aprotinin (Calbiochem), 1% Na-
deoxycholate, 1% Nonidet P-40 (United States Biochemical), 0.5% SDS). Depalmitoylation 
was measured by labeling cells for 3 hours, then incubating for varying time periods in similar 
but non-radioactive media containing 200 [iM palmitic acid (Sigma). After radiolabeling, 
samples were rinsed and lysed directly in high SDS-RIPA buffer for immunoprecipitation. 
Extracts of whole cell fractions were incubated on ice for 1 hour with a mouse 
monoclonal antibody specific for H-Ras (146-3E4, Quality Biotech), or a rabbit anti-caveolin 
antibody (Transduction Labs), coated on fixed Staphylococcus aureus cells (Pansorbin; 
Calbiochem) conjugated to Goat anti-mouse heavy and light chain IgG. The 
immunoprecipitates were washed, resuspended in special sample buffer without P-
mercaptoethanol (2% SDS, 10 mM NaP04, pH7.0, 10% glycerol, 0.05% DTT, and 0.02% 
Bromophenol Blue), resolved by SDS-PAGE, transferred to PVDF membrane and, as needed, 
sprayed with En^Hance (DuPont/NEN) for fluorography or developed with antibody for 
immunoblot analysis. 
Cellular fractionation 
NIH 3T3 cells were rinsed with TBS and scraped into a hypotonic buffer (1 mM Tris 
(pH 7.4), 1 mM MgCl2, 1% Aprotinin (Calbiochem), 1 mM Pefabloc (Boehringer 
Mannheim), 1 ng/mL Leupeptin (Boehringer Mannheim), 1 ^.M Pepstatin (Boehringer 
Mannheim)). Cells were dounced and spun at 100,000 g for 30 minutes. Proteins in the 
cytosolic fraction (SI00) were acetone precipitated. Both the precipitated proteins and 
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particulate fraction (PI00) were solubilized in IX sample buffer. Proteins were separated by 
12.5% SDS-PAGE and transferred to a PVDF membrane. Proteins were then detected by 
immunoblotting. 
Co-Immunoprecipitation 
After treatment, cells were lysed in co-immunoprecipitation buffer (50 mM Tris-HCl 
(pH 7.4), 20 mM MgCl2, 150 mM NaCl, 0.5% (v/v) Nonidet P-40, Aprotinin (20 mg/mL), 1 
mM EGTA, and 1 mM Na3V04). DNA was removed by centrifligation. Antibody against 
H-Ras (146-3E4) or Raf-1 (Santa Cruz) was added for 16 hours at 4 Celsius. Goat anti-
mouse secondary antibody was added to H-Ras samples for one hour, then BSA-coated 
Pansorbin cells were mixed with samples. After gently washing immunoprecipitate with co-
immunoprecipitation buffer, samples were resuspended in sample buffer (2% SDS, 10 mM 
NaP04, pH7.0, 10% glycerol, 1% DTT, 1% p-mercaptoenthanol, and 0.02% Bromophenol 
Blue). Samples were boiled and proteins separated on 12.5% SDS-PAGE gels, then 
transferred to PVDF and analyzed by immunoblotting. 
Immunoblotting 
Proteins collected by acetone precipitation or immunoprecipitation were resuspended in 
electrophoresis sample buffer. After separation by SDS-PAGE, proteins were transferred 
electrophoretically to PVDF membranes and non-specific protein binding was blocked by 
incubating the membrane in 1.25% non-fat dry milk in Tris-buffered saline overnight. 
Membranes were probed with the H-Ras-specific mouse monoclonal antibody, 146-3E4 
(Quality Biotech), a rabbit antibody to Erk-1 (Santa Cruz), or a rabbit antibody to Caveolin-1 
(Transduction Labs). Biotinylated secondary antibodies (anti-mouse or anti-rabbit. Vector 
Labs) were used with development by alkaline phosphatase (Vector) using the manufacturer's 
protocol. 
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RESULTS 
H-Ras mutants bind difTerent percentages of GTP 
Previous results have indicated that the lipid modifications on the C terminus of H-Ras 
are important to efficient effector binding to GTP-bound Ras. GTP binding of H-Ras may 
affect the conformation of the C terminus, which we can monitor by measuring changes in the 
lipid modifications that occur on the C terminus. Using mutants of H-Ras that bind GTP 
differently, we wanted to study whether the GTP-bound conformation had any observable 
effect on palmitate turnover rate on H-Ras. 
Protocols for GTP/GDP determination of H-Ras have used the monoclonal antibody 
Y13-259. In our laboratory, we have found that Y13-259 poorly immunoprecipitates H-Ras. 
In addition, it is not specific for H-Ras, and may bind to K-Ras also. The monoclonal mouse 
antibody 146-3E4 fi-om Quality Biotech strongly binds and immunoprecipitates only H-Ras. 
To optimize and compare the usefulness for both antibodies in the GTP/GDP assay, v-H-
Ras (R12T59) was immunoprecipitated from stably transfected NIH 3T3 cells using either 
antibody 146-3E4 or Y13-259. Similar amounts of the immunoprecipitates were loaded on a 
thin layer chromatography (TLC) plate and GTP and GDP separated using KH2PO4, pH 3.4 
(Fig. lA). Results from two experiments showed that both 146-3E4 and Y13-259 antibodies 
were able to immunoprecipitate GTP-bound H-Ras and retained nucleotide binding 
throughout the immunoprecipitation protocol. However, the 146-3E4 antibody was able to 
more efficiently bind H-Ras, as more nucleotide was observable in the 146-3E4 sample. 
Because 146-3E4 binds H-Ras specifically and more efficiently, it was used in later 
experiments. 
To test whether nucleotide binding to H-Ras affected the C terminus, we confirmed that 
our H-Ras mutants bound to different amounts of GTP. The percentage of GTP-bound H-
Ras in stably transfected cell lines were determined. Wild-type (WT) H-Ras and two 
activated H-Ras mutants, v-H-Ras and 61L, that had been stably introduced into NIH 3T3 
cells were used. After immunoprecipitation of these mutants and then separation of Ras-
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bound nucleotides by TLC, the amounts of GTP and GDP were measured using 
densitometry. The average GTP percentage was calculated from at least three experiments 
for each H-Ras protein (Fig. IB). The percentage of GTP-bound WT H-Ras in low serum 
was 10%, while the activated forms of H-Ras were a little less than 60% in the GTP-bound 
form. The results confirmed the mutants expressed in the NIH 3T3 cells were indeed either 
activated (v-H-Ras and 61L) or primarily GDP-bound (WT). 
Rates of [^H] palmitate incorporation into WT and activated H-Ras are similar 
To test whether palmitoylation of H-Ras occurs at different rates in active and inactive 
conformations, palmitate pulse-labeling experiments were performed with WT and v-H-Ras 
(R12T59) stably transfected NIH 3T3 cells. Cells were labeled with [^H]palmitate for 
various times up to 8 hr. Cycloheximide was included to allow replacement to be monitored, 
rather than palmitate incorporation into newly synthesized protein. H-Ras was 
immunoprecipitated using the 146-3E4 monoclonal antibody and proteins separated by SDS-
PAGE. T he resulting images of the palmitoylated H-Ras on the fluorograph were quantified 
using densitometry and the program ImageQuant. The area on the fluorograph with the 
greatest incorporation of [^HJpalmitate was set at 1, and all other measured areas were 
normalized to this value. The average of three experiments for each H-Ras protein were 
graphed (Fig. 2). Palmitate replacement on both H-Ras proteins occurred rapidly with a 
maximum incorporation happening between 2-4 hours. Then, the [^H] palmitate signal 
decreased slightly after 4 hours. This decrease in labeling has been observed in other proteins, 
including the P adrenergic receptor (18). The mechanism(s) causing this small decrease 
remains hypothetical. Both WT and activated v-H-Ras have equal rates and show similar 
patterns of palmitate incorporation. These results suggest that the conformation of H-Ras 
when bound to GDP or GTP does not affect rates of palmitoylation. 
Individual H-Ras mutants have two rates of depalmitoylation 
Nucleotide binding to H-Ras seemed not to affect palmitoylation. To test whether 
GTP-binding would affect rates of depalmitoylation, pulse-chase experiments were 
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performed to determine palmitate turnover rates of both active and inactive H-Ras. NIH 3T3 
cells expressing WT H-Ras, 61L H-Ras, v-H-Ras, or induced N17 H-Ras were labeled for 3 
hr with [^H] palmitate and then chased with media containing non-radioactive palmitate over 
24 hr. An inducible N17 H-Ras was used because of the lethality of this dominant-negative 
mutant. Over the course of the experiment, the induced protein did not cause observable cell 
death. After the pulse-chase, H-Ras was immunoprecipitated and separated on SDS-PAGE. 
Protein was detected using fluorography. After measuring the amount of palmitate detected 
on the film, data points from at least four experiments for each H-Ras protein were plotted 
on a graph (Fig. 3). Using the scientific graphing program, Graphpad Prism, a best fit double 
exponential decay line was calculated. A double exponential decay was used over several 
other mathematical models including single exponential decay, linear, and polynomial because 
of higher statistical R^ values. Because the best fit line is a double exponential, two palmitate 
turnover half-lives were calculated, one slow and the other fast. 
One possible model that explains why H-Ras would have two palmitate turnover rates is 
that two palmitoylation sites are being deacylated at different rates. This would suggest that 
each site of palmitoylation on H-Ras would have its own rate of palmitate turnover. If that is 
correct, then a singly palmitoylated H-Ras protein would have a single palmitate turnover 
rate. We analyzed this possibility by determining the palmitate turnover rate of a v-H-Ras 
mutant with only one site of palmitoylation. A pulse-chase experiment in 181S v-H-Ras 
NIH 3T3 fibroblasts was done. The results indicate that the palmitate turnover on 181S v-H-
Ras is much faster than any of the dually palmitoylated H-Ras proteins we previously 
studied, but does not seem to fit a single exponential line (Fig. 4). Lu, et al. have also 
performed similar experiments in COS-1 cells with 181S or 184S c-H-Ras mutants having 
only one cysteine available for palmitoylation. Their results concur with ours; that a single 
palmitate on H-Ras has a much faster turnover rate than two palmitates together (20). The 
depalmitoylation rate of a singly acylated H-Ras is certainly more rapid than the natural 
dually palmitoylated protein. However, because [^H] palmitate pulse-chase data for 181S v-
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H-Ras does not fit a single exponential line, the results do not agree with the prediction that a 
single site of palmitoylation would correspond with a single rate of palmitate turnover. 
Activation of H-Ras increases palmitate turnover 
By comparing the depalmitoylation rates we determined, we are able to suggest that 
active H-Ras has a faster palmitate turnover than inactive H-Ras. This was unexpected 
because the rate of palmitoylation of H-Ras seemed unaffected by nucleotide binding. From 
the double exponential lines in Fig. 3, two palmitate turnover half-lives were determined for 
each H-Ras mutant. It is unknown why two palmitate half-lives are indicated. In this study, 
we chose to compare the faster of the two palmitate half-lives, as they correspond to the 
earliest and most linear part of the curve where the majority of data points were collected. 
Table 1 shows the calculated shorter palmitate half-life for each H-Ras mutant studied. The 
graph in Fig. 5 shows the best fit lines from each set of depalmitoylation experiments for the 
H-Ras proteins compared on a single graph. The inset graph compares only the shorter 
palmitate half-lives for all four H-Ras mutants as linear lines on a log plot. We compared the 
shorter half-lives and found that palmitates on the activated 61L H-Ras and v-H-Ras mutants 
have faster palmitate turnover rates than those on the primarily GDP-bound WT and N17 H-
Ras proteins. The fastest rate of depalmitoylation occurs on 61L H-Ras with a palmitate 
half-life of less than an hour. The primarily GDP-bound WT H-Ras had the slowest 
palmitate turnover rate at approximately 2.6 h, which is 2.8 times slower than the turnover 
on activated 61L H-Ras. The palmitate half-lives for H-Ras mutants are, from longer to 
shorter: WT>N17>v-H-Ras>61L. Active mutants of H-Ras have a more rapid palmitate 
turnover than primarily GDP-bound H-Ras proteins. 
The observed relationship between activation state of H-Ras and palmitate turnover may 
be due to the conformational change in the protein upon GTP-binding. If depalmitoylation 
rates are dependent solely upon GTP binding, then with the data gathered, we can 
approximate the rate of palmitate turnover on a single H-Ras molecule when bound to either 
GTP or GDP. When determining the palmitate turnover rates using the H-Ras mutant 
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expressing NIH 3T3 cells, the values were collected from a population of H-Ras proteins 
that contained molecules in both inactive and active conformations. We can solve for a 100% 
or 0% GTP-bound population using the measured amounts of GTP-bound and observed 
palmitate turnover in the WT, 61L and v-H-Ras mutant cell lines. Our calculations result in a 
100% GTP-bound population, or a single GTP-bound H-Ras molecule, as having a palmitate 
half-life of less than 38 minutes. A 0% GTP-bound population, or a single GDP-bound H-
Ras molecule, is predicted to have a 3 hr palmitate half-life. This is a 4.7 times increase in 
palmitate half-life upon GTP-binding. It is important to stress that these calculations assume 
that palmitate turnover rates are affected only by conformation changes occurring upon GDP 
or GTP binding. Our results suggest that the activation state of H-Ras does have some 
relationship to palmitate turnover rates. We are using our data to discern if the two different 
activation states have significantly different palmitate half-lives. 
GTP-Induced effects on H-Ras C terminal modifications do not affect membrane 
binding or localization 
Our data indicates that GTP-binding to H-Ras affects palmitoylation on the C terminus. 
Because palmitoylation of H-Ras is required for efficient membrane binding, it was possible 
that C terminal conformational changes occurring during activation might also affect H-Ras 
association with membranes. To investigate this possibility, the localization of the mutant 
proteins was determined with cell fractionation. WT and v-H-Ras NIH 3T3 cells were 
fractionated into cytosolic (SI00) and particulate (PI00) fractions. The PI00 fraction 
contains all membranes, nuclei, and cytoskeleton. Results of three experiments for each H-
Ras protein showed that the concentrations of both proteins were distributed similarly, with 
approximately <10% of the proteins in the membrane PI 00 fractions (Fig. 6). This indicates 
that the effects of GTP-binding on the C terminus of H-Ras do not increase observable 
amounts of cytosolic H-Ras. 
Others have proposed that Ras proteins change locations on the plasma membrane in 
response to stimulation. Ras has been observed in specialized cholesterol and glycolipid-rich 
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membrane microdomains, termed caveolae (21,22). While GTP-induced effects on the 
palmitoylation of the H-Ras C terminus do not seem to affect over-all membrane binding, 
perhaps H-Ras's affinity for the especially hydrophobic caveloae will be influenced. The 
association of H-Ras and caveolae can be monitored by measuring H-Ras binding to the 
caveolae marker protein, caveolin. H-Ras was gently immunoprecipitated from NIH 3T3 
cells containing WT or v-H-Ras. Washes of the immunoprecipitates were done using a buffer 
containing low concentrations of a non-ionic detergent (0.5% NP-40) to allow any proteins 
that were associated with H-Ras to remain bound. Any caveolin that remained strongly 
associated with H-Ras was detected by Westem-blotting with a polyclonal Caveolin-1 
antibody. Results from two experiments show that both active v-H-Ras and inactive WT H-
Ras were able to bind to caveolin (Fig. 6B). These results indicate that a percentage of 
expressed H-Ras interacts with caveolin and that the C terminal conformation of H-Ras may 
not affect caveolin binding. 
DISCUSSION 
Using palmitate pulse-labeling and pulse-chasing, we were able to characterize the 
palmitate cycling on H-Ras in either primarily GTP or GDP-bound conformations. Wild-
type and activated mutant H-Ras proteins incorporate palmitate at similar rates. However, 
v-H-Ras and 61L H-Ras mutants have faster palmitate turnover rates when compared to WT 
and the dominant-negative N17 H-Ras. The palmitate pulse-chase experiments for all H-Ras 
proteins resulted in a double exponential rate of palmitate removal, indicating two different 
rates of palmitate turnover. In this paper, we have been able to characterize and compare the 
palmitate half-lives on H-Ras in more detail than has previously been reported. 
Models for the observation of two palmitate half-lives on H-Ras 
The results from the [^H] palmitate pulse-chase experiments of all H-Ras mutants best-
fit double exponential curves. From the resulting line equations, a palmitate half-life was 
calculated from each of the exponentials. Though others have measured the depalmitoylation 
of H-Ras and observed similar non-linear lines on log plots, this phenomenon has not been 
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explained(20). We can hypothesize two different models to explain the occurrence of more 
than one palmitate half-life on H-Ras. 
The most obvious model to explain why palmitate pulse-chase data for H-Ras best-fits a 
double exponential curve is that the two sites of palmitoylation on H-Ras have different rates 
of palmitate removal. If this model is correct, we would expect our results from the 
palmitate pulse-chase experiment on the singly palmitoylated 181S v-H-Ras to best-fit a 
single exponential line. However, our data suggests that the data does not fit a single 
exponential line. Additionally, Magee, et. al. measured the palmitate turnover on the 
normally singly palmitoylated N-Ras and found that their data did not fit a linear line on a log 
plot(23). Likewise, the [^H] palmitate pulse-chase data from singly palmitoylated Ga 
proteins do not fit linear lines on a log plot( 17,25). The model suggests that every site of 
palmitoylation will have its own rate of palmitate turnover. Results from this study as well 
as others indicate that a more complex model is required to explain how the rate of palmitate 
turnover on proteins is determined. 
We hypothesize that the localization of H-Ras on the membrane may determine the rate 
of palmitate turnover. H-Ras has been identified in microdomains on the plasma membrane 
called "caveolae"(21,26,27). It has been hypothesized that H-Ras moves in and out of 
caveolae in response to activation(21,22). This would create two separate populations of H-
Ras on the plasma membrane surface, one population residing in caveolae and the other 
outside of these microdomains. It could be possible that the palmitoyl-thioesterase could be 
confined to one of these areas on the membrane, or even be cytosolic. If the palmitoyl-
thioesterase has greater accessibility to one of these populations of H-Ras, then it follows 
that this population would have a rapid palmitate turnover rate. The other population of H-
Ras that had limited accessibility to the deacylase would have a much slower rate of palmitate 
removal. Therefore, [^H] palmitate pulse-chase experiments for H-Ras would be expected to 
result in two palmitate turnover rates: a faster rate for the H-Ras that is more accessible to a 
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deacylase and a slower rate for the less accessible H-Ras. When the palmitoyl-thioesterase is 
identified and characterized, it will be possible to test this hypothesis. 
H-Ras nucleotide binding does not affect palmitate incorporation 
When comparing the palmitoylation of H-Ras mutants, we found that rates of palmitate 
replacement were not affected by GTP-binding. H-Ras bound primarily to GDP (WT) had a 
similar rate of palmitate replacement as a primarily OTP-bound H-Ras (v-H-Ras). It does 
not seem that conformational changes that occur during activation of H-Ras by GTP-binding 
affect the ability of H-Ras to be modified by palmitate. However, the primarily GTP-bound 
H-Ras mutants (v-H-Ras and 61L) did have an increased rate of palmitate removal compared 
to primarily GDP-bound H-Ras proteins (WT and N17). These results indicate that 
nucleotide binding does affect the ability of H-Ras to be depalmitoylated. Why the rate of 
palmitate addition is not affected by GTP binding when the rate of palmitate removal is 
affected is not clear. However, we can speculate about the relationship between palmitate 
addition and removal on H-Ras. 
We hypothesize that depalmitoylation is not rate-limiting. From our observations, the 
rates of palmitate turnover on H-Ras are on the order of hours. However the pulse-label 
experiments indicate that the maximum palmitate addition is reached in less than one hour. 
Because the rate of palmitate removal was slower, it might be assumed that this step in the 
palmitoylation cycle is rate-limiting. This would lead to increased palmitate addition to H-
Ras when the rate of palmitate removal was also increased. Because we did not observe this, 
we must hypothesize that the removal of palmitate from H-Ras is not the rate-limiting step. 
Palmitate turnover is increased when H-Ras is bound to GTP 
When comparing the calculated palmitate half-lives for the H-Ras mutants, we found that 
increased rates of palmitate removal correspond with increased percentages of bound GTP. 
From our palmitate turnover measurements on total cellular H-Ras, we were able to predict 
the palmitate half-life on a single H-Ras molecule when either binding GTP or GDP. We 
found that palmitate(s) on H-Ras bound to GTP could have a half-life more than 4.5 times 
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more rapid than palmitates on H-Ras bound to GDP. From these results, we can conclude 
that nucleotide binding does in fact affect the pabnitoylation of the membrane binding domain 
of H-Ras. 
If palmitoylation at the C terminus of H-Ras is affected by GTP binding, then we can 
hypothesize that the entire membrane binding domain is affected. It may be possible that the 
conformational changes that occur in the Switch II domain of H-Ras can cause some change in 
the conformation of the near-by membrane binding domain. We propose that the membrane 
binding domain of H-Ras could also be responding to activation by changing conformation. 
This C terminal conformation change could reveal palmitates on the C terminus to deacylases. 
The increased accessibility to a deacylase would lead to increased palmitate removal upon 
GTP binding. This juxtamembrane domain model could explain our results that GTP-bound 
H-Ras has a faster rate of palmitate turnover than H-Ras bound to GDP. 
This model has already been applied to the Ga GTPases(17,19). It has been shown that 
activation of Gas by the agonist, isoprotemol, causes increased palmitate turnover on this 
protein. The membrane binding domain of Gas is a palmitoylated N terminus. If it also acts 
as a juxtamembrane domain, then GTP-binding could cause some conformational shift to 
make the palmitoylated residues more accessible to a palmitoyl-thioesterase: increased GTP-
binding caused by an agonist leads to increased palmitate turnover. 
The binding of neuronal Gaz to its effector, adenylyl cyclase, and to its negative 
regulator, Gz-GAP, is inhibited by palmitoylation of its membrane binding domain(12). We 
predict that the lipidated Gaz N terminus could also change conformation in response to 
activation upon GTP-binding. Applying our juxtamembrane domain model to Gaz, we can 
hypothesize that the membrane binding domain plays an important role in Gaz signaling. If 
upon activation the juxtamembrane domain of Gaz makes palmitates at its N terminus more 
accessible to palmitoyl-thioesterases, then we would expect that rates of palmitate turnover 
on Gaz would increase. This might be expected already because agonist-induced activation 
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of the Gaz relative, Gas, leads to increased palmitate turnover. If palmitate cycling on Gaz 
is more rapid upon GTP-binding, then it might be possible that the inhibition of adenylyl 
cyclase and Gz-GAP binding caused by palmitoylation of Gaz might be relieved. This 
would allow the Gaz to interact with downstream targets in the signaling pathway. From 
our juxtamembrane hypothesis, we can predict that future experiments might show : 1) GTP-
binding increases palmitate turnover on Gaz and 2) increased palmitate turnover leads to 
increased effector and negative regulator binding to Gaz. 
H-Ras C terminus as a juxtamembrane domain 
The conformational changes that occur upon GTP-binding to H-Ras have been well 
characterized in the Switch I and Switch II regions. These conformational changes have been 
thought to be those required for efficient effector binding to Ras. However, another region of 
Ras has been shown to affect Raf kinase binding. The C terminus of Ras must normally be 
lipid-modified for efficient and direct binding of the Raf kinase zinc finger domain to the Ras 
protein(lO). It may be possible that conformational changes to H-Ras upon GTP-binding 
might also include changes at its C terminus. 
Our results show that the membrane binding domain of-H-Ras responds to GTP binding. 
Our results also show indirect evidence of this in the form of changes to palmitoylation of H-
Ras. Additional effects from the conformational changes of the H-Ras C terminus could be 
occurring. Therefore, the membrane binding domain, or juxtamembrane domain, of H-Ras may 
play a role in signal transmission or cessation. We hypothesize that other GTPases will 
share this juxtamembrane motif and play a role in their signaling. 
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FIGURE LEGENDS 
Fig. 1. Percentages of GTP in various H-Ras proteins were determined. ( A )  NIH 
3T3 cells stably transfected with v-H-Ras (R12T59) were labeled with [^^P] inorganic 
phosphate. H-Ras was immunoprecipitated with either 146-3E4 (Quality Biotech) or Y13-
259 (Calbiochem) antibody. (5) NIH 3T3 cells stably transfected with wild-type (WT), v-
H-Ras, or 61L H-Ras were labeled with [^^P] inorganic phosphate and H-Ras 
immunoprecipitated with 146-3E4 antibody. Nucleotides were separated by thin layer 
chromatography in KH2PO4, pH 3.4. Labeled nucleotides were detected by autoradiography 
at -70 C for 4-31 days and quantified using densitometry. The calculated percentage GTP is 
an average of at least 3 experiments. 
Fig. 2. Falmitate is incorporated into WT and v-H-Ras at equal rates. ( A )  WT and 
(5) R12T59 stably transfected NIH 3T3 cells were pulse-labeled with [^H] palmitate over 8 
70 
hours. H-Ras was immunoprecipitated using 146-3E4 antibody. Proteins were separated 
using SDS-PAGE and transferred to PVDF membranes. Membranes were sprayed with 
En^Hance and put on film at -70 C for 9-30 days. (C) The amount of H-Ras protein on the 
membrane was detected by immunoblotting with 146-3E4. Palmitate and protein bands were 
quantified with ImageQuant. The palmitate was normalized to the relative protein amounts 
and graphed. The black line represents the WT data and the gray points the 
unphosphorylated R12T59 data. The data points are an average of at least 3 separate 
experiments. 
Fig. 3. Palmitate pulse-chase experiments reveal two palmitate half-lives In H-
Ras. (/4) N17 H-Ras, {B) WT H-Ras, (Q 61L H-Ras, (D) v-H-Ras stably transfected NIH 
3T3 cells were labeled with [^H] palmitate. Cells were pulse-chased with non-radioactive 
palmitate over 24 hr. H-Ras was immunoprecipitated with 146-3E4 and separated by SDS-
PAGE. Proteins were transferred to PVDF and sprayed with En^Hance. Membranes were 
put on fibn for 3-40 days at -70 C. The membrane was then developed with 146-3E4 
antibody by immunoblotting. Relative palmitate and protein amounts were determined with 
ImageQuant. Normalized palmitate amounts were graphed. A best fit line (double 
exponential) was calculated from the data from at least 4 experiments for each H-Ras protein 
using the GraphPad Prism software program. 
Fig. 4. The palmitate half-life on 181S H-Ras is much shorter than on dually 
palmitoylated H-Ras. (A) 181S H-Ras stably transfected NIH 3T3 cells were labeled with 
[^H] palmitate for 3 hr. The cells were pulse-chased with non-radioactive palmitate over 8 hr. 
H-Ras was immunoprecipitated and separated by SDS-PAGE. Proteins were transferred to 
PVDF. Palmitoylated H-Ras was detected by fiuorography using En^Hance. The membrane 
was on film for 26 days at -70 C. H-Ras proteins were detected by developing the membrane 
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with 146-3E4 immunoblotting. (B) Palmitoylated H-Ras and H-Ras proteins were quantified 
using ImageQuant and normalized. Data points from one experiment were graphed. 
Table 1. The palmitate turnover of a single H-Ras molecule in either the GTP or 
GDP bound conformation was calculated. The percentage of GTP-bound H-Ras in several 
H-Ras activation mutant populations and the shorter palmitate half-lives from the calculated 
line equations were used to determine the palmitate half-life of a single H-Ras molecule when 
in a GTP or GDP conformation. A linear relationship was defined between the % GTP and 
palmitate half-lives observed. The calculation assumed that the activation conformation of H-
Ras is the only factor in palmitate turnover rates. 
Fig. 5. Active H-Ras mutants have shorter palmitate half-lives than WT or 
inactive H-Ras mutants. The best fit palmitate pulse-chase lines from WT (gray —), N17 
(gray solid), v-H-Ras (black solid), and 61L H-Ras (black —) were compared on a single 
graph. The determined line equations were used to compose the inset graph, which compares 
only the shorter calculated palmitate tumover rates. Using the equation for the shorter 
palmitate half-life, a linear line for each H-Ras protein was graphed on a log plot. 
Fig. 6. H-Ras mutants with increased palmitate turnover rates continue efficient 
membrane association. (A) WT and v-H-Ras stably transfected NIH 3T3 cells were 
fractionated into cytosol and membrane particulate fractions by centrifiigation at 100,000 g 
for 30 min in a hypotonic buffer. Proteins were separated by SDS-PAGE and transferred to 
PVDF. H-Ras was detected by immunoblotting with 146-3E4 antibody. Relative amounts 
of protein in the SI GO and PI 00 were quantified using ImageQuant software. The experiment 
was performed at least three times. (B) H-Ras proteins in WT and v-H-Ras stably fransfected 
NIH 3T3 cells were co-immunoprecipitated using 146-3E4 antibody in a gentle lysis/wash 
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buffer, then separated using SDS-PAGE. CaveoUn-1 and H-Ras were detected using 
caveolin-1 and 146-3E4 antibodies. This experiment was performed twice. 
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Ab: C 146 C 259 WT vHRas 61L 
74 74%GTP 10.1 58.4 57.7 %GTP 
Figure 1. 
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Table 1. Calculation of Palmitate turn-over on a single H-Ras molecule 
Cell Line %GTP Palmitate half-life 
(hr) 
WT H-Ras 10.1 2.7 
v-H-Ras 58.4 1.6 
61L H-Ras 57.7 0.9 
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CHAPTER 4: CONCLUSIONS 
Summary 
The purpose of the on-going research in the Buss laboratory is to better understand the 
lipid modifications of proteins. In this body of work, the reversible palmitoylation of H-Ras 
was studied. In finding regulatory mechanisms of this modification, it is hoped that we will 
be better able to find a way to affect the activity of the H-Ras protein. H-Ras is an oncogene 
and any understanding of how it functions and is regulated could be important to future 
cancer therapies. In this work, I have described results that indicate the palmitoylation of H-
Ras can be modified by exogenous treatment with oxidants and may be regulated according to 
its activation state. 
In treating NIH 3T3 cells with multiple oxidants as cells were simultaneously labeled 
with [^H] palmitate, the palmitate replacement on H-Ras is increased. The turnover of 
palmitate on H-Ras is also increased upon oxidant, specifically S-nitrosocysteine, treatment. 
What this increased palmitate cycling on H-Ras signifies to the activity of the protein was 
tested by directly observing the activation state via GTP binding. Interestingly, the 
percentage of GTP bound to H-Ras decreases upon SNC treatment. Coinciding with the 
decrease in activated H-Ras is a decrease in Erk response to serum stimulation, indicating that 
SNC is decreasing downstream signaling through H-Ras. With these data, we cannot yet 
suggest that increased palmitate turnover leads to deactivation of H-Ras or vice versa. We are 
unable to dissect the two responses to SNC (increased palmitate turnover and decreased GTP 
binding) at this time. However, we have identified and characterized a new tool that can be 
used to alter the palmitate turnover rate on H-Ras. 
Additionally, it seems that H-Ras palmitoylation responds to the activation state of the 
molecule. In other signaling proteins, including a similar GTPase Gsa, activation in response 
to stimulation coincides with an increase in palmitate turnover. To test whether this 
coincidence occurs in H-Ras, I measured the palmitate half-lives of differently activated H-
Ras proteins, including wild-type, dominant-negative N17, oncogenic 61L H-Ras and 
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activated v-H-Ras. The data from [^H] pulse-chase experiments fits a double exponential 
line, based on values and observation, indicating that there are two half-lives for palmitate 
on H-Ras. Comparing the shorter of the two half-lives from each H-Ras protein expressed 
showed that the active H-Ras proteins, 61L and v-H-Ras, have more rapid palmitate turnover 
rates than the primarily GDP-bound WT and N17 H-Ras proteins. Earlier studies have 
shown that increased palmitate cycling on the GTPase Gsa after agonist stimulation leads to 
decreased membrane binding. Results of sub-cellular fractionations indicate that increased 
palmitate tumover rates on activated H-Ras do not cause a release of the protein into the 
cytosol. The purpose and relationship between increased palmitate tumover and H-Ras 
activation state is still not clearly understood. However, these results again suggest that the 
palmitoylation of H-Ras is able to be regulated and could possibly be affected by H-Ras 
stimulation in vivo. 
Future Study 
The oxidant with the greatest effect on [^H] palmitate incorporation was a small 
nitrosothiol, S-L-nitrosocysteine (SNC). I hypothesize that SNC targets H-Ras because of 
its ability to cross the plasma membrane through L-type amino acid transporters. My 
hypothesis assumes that the nitric oxide radical is not the instigator in the changes in 
palmitate tumover, as the nitric oxide producers, NOC-15 and NOC-18, do not cause as great 
a change in palmitate tumover as SNC. Future work could be to define a more complex model 
of the nitric oxide or nitric oxide metabolite that is affecting the palmitate tumover on H-Ras. 
Identifying the nitric oxide metabolite responsible for the increased palmitate cycling on 
H-Ras would allow a model to be designed describing how the palmitoylation on H-Ras is 
being affected. Of the multiple oxidants used as treatments in this study, most had some 
effect on the palmitate replacement on H-Ras. Each of these oxidants could be used 
independently and their effects characterized more frilly, including dose and time 
dependencies. In addition, the specificity of SNC could be frirther characterized by 
investigating the role of the L-type amino acid transporter in SNC's import into the cell. This 
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could be done extensively using molecular genetics and cell expression of the transporter, or 
simply with an inhibitor of the channel. The oxidant effects on palmitoylation on H-Ras, and 
many other proteins as well, is an important finding that should be better characterized. In 
this work, the beginning foundation has been laid by finding specificity of SNC effect on H-
Ras palmitoylation. Future experiments will lead to a greater understanding of oxidant effects 
on lipid modifications and the resulting outcome this will have on the function of proteins. 
H-Ras palmitoylation is also affected by the activation state of the protein. 1 have 
shown this by using wild-type and mutant H-Ras expression in NIH 3T3 cells. While 
activated mutants show an increase in palmitate turnover, the method of this increase has not 
been determined. With activated mutants of H-Ras, NIH 3T3 cells are transformed. This 
includes a change in morphology as well as uncharacterized alterations in expression of many 
protein (1,2). So, in addition to the increased GTP-binding we know is occurring in the 
activated H-Ras mutants, all of these other differences exist in the transformed cells compared 
to the wild-type and N17 dominant negative H-Ras transfected cells. 
To determine if the increased palmitate turnover on H-Ras is dependent solely on GTP 
or GDP conformation state, stimulation of wild-type H-Ras transfected NIH 3T3 cells with 
agonists for the H-Ras pathway (ie. EGF or PDGF) could be used to activate the quiescent 
H-Ras. The palmitate modification on H-Ras could be monitored simultaneously. Several 
problems exist for these experiments however. Current [^H] palmitate labeling methods 
require use of serum to solubilize the hydrophobic fatty acid before addition to media (3). 
Serum contains unknown amounts of growth factors that would continuously stimulate GTP-
binding on H-Ras. This problem might be over-come by using albumin rather than serum to 
solubilize the radioactive lipid. An additional challenge in using agonist stimulation is that 
%GTP binding increases by approximately two fold when H-Ras is stimulated by growth 
factors (4-6). So, if the basal %GTP bound is approximately 10% as our results show, then 
stimulation will cause this to increase to only approximately 20%. When working with 
activated mutants, H-Ras was bound to approximately 60% GTP. The slight increase in 
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GTP binding of WT H-Ras might not cause a great enough increase of palmitate turnover to 
be observed with current methods. However, it may be important to evaluate whether 
growth factor stimulation alone can cause an increase in palmitate turnover, as this is the 
normal situation in vivo. 
If the increased palmitate turnover on H-Ras is a result of NIH 3T3 cells transformation, 
this possibility needs to be addressed as well. Activated H-Ras causes many cell changes, 
including changes in a protein's expression and morphology (1,7). It is possible that a 
concurrent effect of cell transformation is the cause of the observed palmitate turnover on H-
Ras. This possibility was addressed somewhat by measuring the palmitate half-lives of N17 
H-Ras and 61L H-Ras as transient expressions in COS cells. Palmitate turnover rates were 
significantly different between these proteins, while the COS cells did not show 
transformation indicating that gross transformation of cells may not be the cause of increased 
palmitate cycling on H-Ras. However, fliture experiments could continue this line of inquiry. 
One experiment that could address whether transformation of NIH 3T3 cells alone can 
cause an increase in palmitate turnover on H-Ras could utilize cells transformed by another 
oncogene product. v-Raf and WT-H-Ras co-tranfected NIH 3T3 cells would provide a cell 
line that is transformed as a result of an oncogene product in the Ras-Raf signaling pathway. 
However, H-Ras would be in a primarily GDP-bound conformation. If palmitate turnover on 
H-Ras is still increased in these cells, then this would indicate that cell transformation is the 
cause of the effects observed on palmitate cycling on H-Ras. 
One effect of activated H-Ras induced cell transformation is an increase in superoxide 
production (8). Superoxide is a oxygen metabolite radical that reacts with nitric oxide radicals 
to form peroxynitrite (ONOO-). Both the superoxide and peroxynitrite product are 
cytotoxic and used in immunological response for cell-killing (9). In this dissertation, I have 
shown several oxidants can increase the palmitate turnover on H-Ras. I suggest that the 
increased superoxide production induced upon cell transformation may be the cause of 
observed increase in palmitate turnover on activated H-Ras mutants, 61L and v-H-Ras. 
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Several experiments could be performed to test this hypothesis. The authors of the 
paper that discovered activated v-H-Ras transformed NIH 3T3 cells produce increased 
superoxide also identified at least one pathway responsible for superoxide production. When 
co-expressing a dominant negative Rac protein, this superoxide production was inhibited, 
indicating that the small GTPase, Rac, is involved in the production of superoxide in these 
transformed cells (8). By co-expressing v-H-Ras and dominant negative Rac, it would be 
possible to test whether the observed increase in palmitate turnover on v-H-Ras was a result 
of the superoxide produced through a Rac pathway. Likewise, co-expressing a WT H-Ras 
and an activated Rac could be used to test if palmitate turnover would be increased in the WT 
H-Ras in response to expected superoxide production through activated Rac pathways. The 
possibility that oxidant production, specifically superoxide here, might be a endogenous 
regulator in the palmitate cycling of H-Ras is very interesting, and in my mind, an important 
direction for future study. 
If endogenously produced oxidants do indeed play an important role in the palmitate 
turnover on H-Ras, then this could lead to another avenue of study. Several established cell 
lines can be stimulated to produce micromolar amount of nitric oxide radical and its 
metabolites. One such cell line, RAW 264.7, are mouse monocyte-macrophage cells that can 
be stimulated with interferon (IFN) and lipopolysaccharide (LPS) to produce NO (10). An 
experimental set-up could be designed where these cells are grown in co-culture with WT H-
Ras transfected NIH 3T3 cells. Upon IFN and LPS stimulation, RAW cells would produce 
NO which could be metabolized over several hours to days. The effects of prolonged 
exposure to endogenously expressed oxidants on palmitate turnover on H-Ras could be 
analyzed. The effects of prolonged NOx exposure could also be measured on several 
palmitoylated proteins, as our results with exogenous oxidant treatment modified the 
palmitoylation of many proteins in the cell lysate. 
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Impact on Field of Lipid Modifications 
The results from this work show that the palmitate turnover rates on H-Ras can be 
modified in two separate cases, oxidant treatment and activation. These discoveries are 
important to the study of H-Ras and its oncogene product because they begin to unravel the 
relationship between reversible palmitate modification and protein fianction. We have 
identified and characterized a new tool which increases the palmitate cycling on H-Ras and 
modifies palmitoylation on several proteins. We have also shown that activated H-Ras has 
an increased palmitate turnover rate than normal WT H-Ras, though the cause of this is still 
unknown. These findings may be important to researchers in development and cancer studies 
as H-Ras fiinctions in so many important pathways regulating cell growth, apoptosis, and 
differentiation. 
Additionally, these results are important to those researchers studying the palmitate 
modifications of other proteins. Less than 20 years ago, viral glycoproteins were found to be 
palmitoylated. The lipid modification was thought only to increase the hydrophobicity of 
the proteins for better membrane binding (11). In this short time, many more proteins have 
been identifed that are palmitoylated. When the reversibility of the modification was 
discovered, researchers began to hypothesize a link between protein function and palmitate 
turnover. Only a few proteins have been studied by ourselves and others trying to discern 
the role of reversible palmitoylation and protein function. 
The results in this dissertation describe another example of the regulation of 
palmitoylation on a protein. Our results suggest a relationship does exist between activation 
of H-Ras and its palmitate turnover. These results fiirther substantiate the hypothesis that 
the palmitate modification of proteins is directly involved in the fianctioning of the protein. 
While this dissertation does not answer that question in its entirety, the results have provided 
several keys to help in future study. 
However, not only the results, but the procedures used will benefit fiature study in lipid 
modifications. Oxidants, especially the nitrosothiol S-nitrosocysteine, can now be used to 
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alter the palmitate turnover of proteins in the study of lipid modification and protein 
function. Additionally, the methodologies used in these experiments have been altered and 
optimized so that future work can proceed using improved procedures. More accurate 
results can be gained by using the ["H] palmitate pulse-label and pulse-chase techniques we 
have utilized. Likewise, the use of SNC, a quickly metabolized nitrosothiol, has been 
described in more detail for fiiture experiments. So not only do our results impact the study 
of lipid modifications, but our improved techniques can also be used by others in later 
research. 
Palmitoylation on H-Ras is an important area of study. I believe that in the coming 
years, researchers will begin to find more relationships between proteins and their regulation 
by palmitoylation. It seems that researchers are finding that their proteins of study are 
reversibly palmitoylated. As yet, the purpose of the palmitate addition to the proteins is not 
always obvious. I believe that research in lipid modifications is in its infancy, just beginning 
to grow. As more and more proteins are identified with reversible palmitate additions, the 
importance of this modification is going to be realized. It is my hope that the results and 
improved methods presented here will be used in those future studies. 
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